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Abstract 
 
Breast cancer is the most common cancer among women worldwide. Nevertheless only few good 
breast cancer mouse models exist so far. In order to generate a novel in vivo breast cancer model, 
two new tools for mouse genetics were developed. First, female stem cells were characterized and 
chimeras from those female stem cells carrying the Polyoma Middle T (PyMT) oncogene were 
derived successfully. In the future, this cell line will be used for laser assisted injection into 8-cell 
stage embryos to rapidly produce F0 mice that are fully derived from the embryonic stem cells (ESCs) 
and therefore can be used directly for phenotyping without further breeding. Second, to facilitate 
the generation of mice targeted at the ROSA26 locus, an exchange vector system was developed, 
that drastically reduces time and effort needed to target transgenes into ESCs. Using this system 
mouse lines can be generated, that express different shRNAs from the ROSA26 locus, in order to 
knock down candidate breast cancer genes on a sensitized background. 
 
A second project aimed to examine the role of MKK7 in the LPS/GalN induced hepatitis model. The 
MKK7-JNK-MAPK pathway is known to play an important role in TNFα-induced liver inflammation. 
Hepatocyte specific deletion of MKK7 did not affect the extent of liver damage following LPS/GalN 
treatment. Likewise, survival as well as serum transaminase levels (ALT and AST) were found to be 
similar between control mice and mice lacking MKK7 in the liver and the hematopoietic system, 
indicating a similar hepatic damage. Furthermore, loss of MKK7 in the liver and the hematopoietic 
system was associated with a reduced basal expression of c-Jun mRNA. However, upon LPS/GalN 
treatment normal induction of c-Jun mRNA was observed. Interestingly, no induction of c-Jun protein 
was observed in knockout mice, indicating that the loss of MKK7 rather affects either mRNA stability, 
translation, protein stability or posttranslational modifications. Taken together, loss of MKK7 in the 
liver and the hematopoietic system in the context of LPS/GalN induced hepatitis was shown to affect 
the expression of certain genes (c-Jun, Tnfα) and proteins (c-Jun) but not the overall outcome after 
induction of hepatitis. 
 
  
   
Kurzfassung 
 
Brustkrebs ist die häufigste Krebserkrankung bei Frauen weltweit. Trotzdem stehen bis heute nur 
wenige gute Mausmodelle für Brustkebs zur Verfügung. Zwei innovative Entwicklungen sollen helfen, 
einen in vivo Brustkrebs-Screen zu ermöglichen. Die Stammzellqualitäten einer weiblichen 
embryonalen Stammzellline wurden nachgewiesen und chimäre Mäuse, welche das 
Polyoma Middle T (PyMT) Onkogen exprimieren, wurden erfolgreich erzeugt. In der Zukunft sollen 
diese embryonalen Stammzellen (ESZ) in Mausembryos im 8-Zellstadium injiziert werden. Das 
ermöglicht die Herstellung von F0 Mäusen, die vollständig von den ESZs abstammen und somit eine 
Analyse des Phänotyps in der ersten Generation erlauben. Um das Generieren von ESZs mit 
Manipulationen im ROSA26 Lokus zu erleichtern, wurde ein Exchange Vector-System entwickelt, um 
den Zeit- und Kostenaufwand zur Herstellung ROSA26-mutanter Mäuse drastisch zu reduzieren. Mit 
Hilfe dieses Systems sollen mehrere Mauslinien erzeugt werden, die verschiedene shRNAs in ihrem 
ROSA26 Lokus tragen. Diese shRNAs werden folgendermaßen gewählt, dass sie verschiedene 
Moleküle der PyMT-Signalkaskade ausschalten und dadurch möglicherweise den Verlust des 
onkogenen Potenzials von PyMT verursachen. Bei der eigentlichen Anwendung im in vivo Brustkrebs-
Screen werden die shRNAs in die PyMT-exprimierenden ESZs eingebracht, um die Funktionsweise 
von PyMT im Zusammenhang mit der malignen Transformation in der F0-Generation zu erforschen. 
 
Ein zweites Projekt hatte zum Ziel, die Rolle der Stresskinase MKK7 im LPS/GalN induzierten 
Maushepatitismodell zu analysieren. Es ist bekannt, dass der MKK7-JNK-MAPK-Signalweg von großer 
Bedeutung für die Entstehung von TNFα-stimulierter Hepatitis ist. Hepatozytenspezifische Deletion 
von MKK7 hatte keinen erkennbaren Einfluss auf das Ausmaß des Leberschadens nach Behandlung 
mit LPS/GalN. Auch bei Mäusen mit einer Deletion von MKK7 in der Leber als auch im 
hämatopoietischen System waren die Serumtransaminaselevel (ALT und AST) unverändert 
gegenüber der Kontrollgruppe. Des Weiteren konnte eine reduzierte Basalexpression von c-Jun 
mRNA bei diesen Knockoutmäusen festgestellt werden, wohingegen die Transkription von c-Jun 
mRNA in Folge der Hepatitisinduktion unverändert gegenüber den Kontrolltieren war. 
Interessanterweise wurde ein vollständiger Verlust der Induktion von c-Jun-Protein in 
Knockoutmäusen erfasst. Diese Beobachtungen deuten auf einen Einfluss von MKK7 auf die mRNA-
Stabilität, Translation, Proteinstabilität oder posttranslationale Modifikationen hin. 
Zusammenfassend konnte gezeigt werden, dass Verlust von MKK7 in der Leber und dem 
hämatopoietischen System im Kontext von LPS/GalN-induzierter Hepatitis einen Einfluss auf die 
Expression bestimmter Gene (c-Jun, Tnfα) und Proteine (c-Jun) hat. 
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1 PART 1: New Tools for Mouse Genome Engineering 
 
1.1 Introduction 
1.1.1 Mouse genome engineering 
 
Over the last decades the mouse (Mus musculus) has become the premier genetic vertebrate model 
(Nguyen & Xu 2008; Glaser et al. 2005). Humans and mice display a high overall similarity in terms of 
physiology, anatomy, metabolism as well as tissue structure and organization and mice can develop 
diseases, that closely resemble the pathologies seen in human patients (Raymond & Soriano 2006). 
With the completion of the mouse and human genome sequences, the importance and power of the 
mouse as a genetic model for human biology became even more evident. Both genomes are highly 
similar and for almost every human gene a murine counterpart can be found (Gunter & Dhand 2002). 
Moreover, 96 % of these genes are located within syntenic regions of mouse and human 
chromosomes, indicating that the arrangement is evolutionary conserved. The median amino acid 
sequence identity of the encoded proteins of all analyzed orthologous gene pairs is 78.5 % (Boguski 
2002). Thus, the mouse is a powerful tool to define gene function that underlies human physiology 
and pathology with respect to comparative genomics. 
Historically, research was contingent on mice with naturally occurring spontaneous mutations. These 
mutations were identified by an altered phenotype and then the genotype was analyzed using 
primarily forward genetic approaches (Nguyen & Xu 2008). In contrast, reverse genetic technologies 
alter specific genes of the genome in order to determine their function by examining the resulting 
phenotypes (Figure 1). During the last years many powerful tools to genetically modify mice have been 
developed, some of them will be discussed in the next sections. 
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Figure 1: Comparison of reverse and forward mutagenesis strategies. For the reverse genetics approach a 
preselected gene is manipulated in vitro in embryonic stem cells (ESCs) that are used to generate a mutant 
mouse strain. The phenotypic characterization of the mutant should reveal the essential, nonredundant 
function of the targeted gene. By contrast, forward genetics randomly mutagenizes a large number of genes in 
vivo. Upon breeding of the founder generation relevant mutant offspring are identified by phenotypic 
screening. The altered gene must be identified by genetic mapping and sequence analysis. Figure and Figure 
legend adapted from (Kühn & Wurst 2009). 
 
1.1.1.1 Tools for mouse mutagenesis 
 
Reverse genetic methods include amongst others gene targeting, gene trapping, in vitro chemical 
mutagenesis and RNAi mediated gene knockdown (Kühn & Wurst 2009). Gene trapping vectors 
inactivate and report the expression of the trapped gene and provide a molecular tag for its 
identification (De-Zolt et al. 2009). Both, gene trapping and chemical mutagenesis can be used to hit a 
large number of genes in vitro in order to establish libraries of mutant embryonic stem cells (ESCs). 
These libraries can then be screened by qPCR or sequencing to identify clones that harbor mutations 
in a specific gene of interest (Kühn & Wurst 2009). 
3 
 
With gene targeting it is possible to introduce defined modifications as deletions, insertions or point 
mutations at specific locations in the mouse genome (Tessarollo et al. 2009). This is achieved by 
homologous recombination (HR) between a targeting vector and the endogenous locus. As HR of the 
vector occurs infrequently, there need to be ways to discriminate between HR and random 
integration. The most commonly used positive selection marker is a neomycin (neo) resistance gene 
cassette, which confers resistance to geneticin (G418). Furthermore, screening methods such as 
Southern blotting and long-range PCR are needed to prove the correct HR at a defined locus (Simon et 
al. 2009). As the construction of a gene-targeting vector by PCR and standard cloning techniques is 
time consuming, methods have been developed that allow a much faster assembly of targeting 
vectors (Kühn & Wurst 2009). One of these methods is recombineering in Escherichia coli (E. coli). This 
method utilizes functions encoded either by λ phage or cryptic phage Rac to induce rapid and highly 
efficient HR (Lee et al. 2009). 
There are two considerable disadvantages concerning conventional gene targeting approaches. First, a 
gene deletion may result in embryonic lethality. Second, by exerting its effect in multiple cell and 
tissue types, a gene ablation could create a complex phenotype in which it is difficult to discriminate 
between the direct function in a particular tissue and secondary effects resulting from altered gene 
function in other tissues. To avoid these problems, strategies for conditional gene deletion have been 
developed. These strategies make use of site-specific recombinases (SSRs), which are derived from 
recombination systems of yeast or bacteriophages (Wang 2009; Simon et al. 2009). SSRs bind and 
cleave specific short DNA sequences, exchange two involved DNA strands and rejoin the DNA strands, 
thereby rearranging DNA segments between two strands. Thus the SSR systems can be seen as 
“switches”, allowing activation or silencing of the desired gene (Birling et al. 2009). The expression of 
the recombinase can be achieved using viruses or by crossing the mice to a recombinase expressing 
transgenic mouse line. The most widely used system in mice is the Cre/loxP system (Gu et al. 1993). 
Another very similar system is the Flp/frt system (Dymecki 1996). Although the Flp/frt system could be 
used instead of the Cre/loxP system to make a conditional deletion, this is done quite rarely because 
the number and diversity of available Cre transgenic lines is much higher than that of Flp transgenic 
lines. The Flp/frt system is therefore still mainly used to remove the selection markers (Simon et al. 
2009). The recently discovered Dre/rox system acts in a similar way as the aforementioned systems 
(Anastassiadis et al. 2009). The ΦC31 integrase mediates recombination between attP and attB sites 
to produce attL and attR sites, which are inert to further ΦC31-mediated recombination events 
(Birling et al. 2009). Thus, the ΦC31 integrase is the ideal tool for transgene insertion or cassette 
exchange. 
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Recombination can be controlled spatially and temporally by expressing the recombinase under the 
control of a tissue or cell type specific promoter or fused with the ligand-binding domain of either the 
estrogen, glucocorticoid or progesterone receptor (Wang 2009; Feil et al. 1996; Kellendonk et al. 
1996). In the latter situation, the fusion protein is sequestered in the cytoplasm in absence of the 
adequate steroid. Upon ligand binding, it translocates to the nucleus, free to mediate recombination. 
In order to prevent binding and interference of endogenous steroids, mutations have been introduced 
in the ligand binding domains, allowing induction only by special synthetic steroids, such as tamoxifen 
(Birling et al. 2009). Another way to control transgene expression is the tetracycline (Tet)-inducible 
expression system, which exists in two basic variants, the tTA (Tet-off) system and the rtTA (Tet-on) 
system (Sun et al. 2007). 
RNA interference (RNAi) can serve as an alternative to classical gene targeting by HR. It can be used for 
rapid functional genomics and also facilitates large-scale screens (Glaser et al. 2005). RNAi is a 
sequence-specific gene silencing process at the mRNA level. In mammalian cells, long double-stranded 
RNAs (dsRNA; >30 bp) lead to an interferon response that causes a global inhibition of protein 
synthesis and non-specific mRNA decay. Small interfering RNAs (siRNAs; <30 bp) on the other hand are 
able to direct the knockdown of specific mRNAs without interferon activation (Hitz et al. 2009). This 
mechanism can be used as an efficient method to silence gene expression in mammalian cells either 
transiently by transfection of siRNAs or stably by transcription of short hairpin RNAs (shRNAs) from 
expression vectors or retroviruses (Rubinson et al. 2003). Retroviral delivery or pronuclear DNA 
injection can lead to a random integration of the expression vector, which makes it impossible to 
control the number of integration events. However, single-copy RNAi constructs can be placed into 
the ROSA26 locus of ESCs (Hitz et al. 2009). By targeting of genes to the ROSA26 locus, ubiquitous 
expression of the transgene during development and in the adult is facilitated (Soriano 1999). The 
amount of shRNA transcribed from one single vector sequence integrated into the ROSA26 locus is 
sufficient for efficient gene knockdown (Hitz et al. 2007). The shRNA transgenic progeny can be either 
directly phenotyped or, in case of conditional shRNA vectors, crossed to a Cre transgenic strain (Hitz et 
al. 2009).  
 
1.1.1.2 Pluripotent stem cells for mouse engineering 
 
The basis of generating mice specifically altered in a certain locus are pluripotent stem cells. There is 
no uniformly accepted definition for stem cells (Potten & Loeffler 1990). One possible definition says 
that a cell has to comply with three requirements to be considered as a “stem cell”. First, it is not 
specialized for any particular function. Second, under proper conditions the cell is able to differentiate 
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into a more specialized cell type. And third, it can also reproduce itself indefinitely (Hemmat et al. 
2010). The process of generating different daughter cells - one cell that is commited to lineage-specific 
differentiation and one stem cell - is called asymmetric cell division, which is considered as a hallmark 
of all stem cells (Knoblich 2008). Totipotent and pluripotent cells are equal in their ability to form all 
cell types of the embryo and adult, including germ cells, but only totipotent cells are additionally 
capable to give rise to extra-embryonic structures (Mummery et al. 2011b). Totipotent cells can be 
derived while the fertilized egg is still a zygote and during the first four blastomere cleavage phases 
(Hemmat et al. 2010). Pluripotent stem cells can be derived from various sources (Yu & Thomson 
2008). 
In the 1950s scientists began the study of teratocarcinomas, which are malignant germ cell tumors 
that comprise undifferentiated as well as a differentiated components including all three germ layers 
(Yu & Thomson 2008). As these tumors develop very rarely, real progress in this field could only be 
made when in 1954 Stevens and Little found a high incidence of teratocarcinomas in male 129 mice. In 
1970 Kahan and Ephrussi managed to isolate stem cells from teratocarcinomas that could be stably 
propagated in vitro and during the early 1970s the first mouse embryonal carcinoma (EC) cell lines 
could be established and used to study development (Yu & Thomson 2008; Stevens & Little 1954; 
Kahan & Ephrussi 1970). These EC cells resemble undifferentiated ESCs of the mouse blastocyst stage 
embryo in many respects (Mummery et al. 2011a). Some EC cell lines are even capable of contributing 
to various somatic cell types upon injection into mouse blastocysts, but most EC cell lines have limited 
developmental potential and contribute only poorly to chimeric mice, which probably is due to the 
accumulation of genetic changes during malignant transformation (Yu & Thomson 2008). 
Mouse ESCs are the most widely used source of pluripotent stem cells. In vivo pluripotent cells are 
present only transiently in the early embryo, as they quickly differentiate into various somatic cells. In 
1981 scientists first managed to derive ESC lines from the inner cell mass (ICM) of mouse blastocysts 
(Evans & Kaufman 1981; Martin 1981). As other pluripotent cell lines, ESCs can be cultured 
indefinitely, differentiate into a wide variety of cell types in vitro and form teratocarcinomas when 
injected into mice. Their tremendous advantage is that they are karyotypically normal (euploid) and 
contribute at high frequency to all kind of tissues in chimeras, including germ cells. These 
characteristics make them the ideal tool for introducing modifications into the mouse germline (Yu & 
Thomson 2008; Mummery et al. 2011a; Evans & Kaufman 1981; Martin 1981). However, these cells 
have an innate tendency to differentiate into specialized cell types that compose the embryo. For the 
culture and experimental use of ESCs it is therefore essential to inhibit this differentiation process. 
This is achieved by the set-up of sophisticated culture conditions. The two most important features of 
the ESC culture settings are the co-culture with “feeder” cells, which are mitotically inactivated mouse 
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embryonic fibroblasts (MEFs) and the addition of leukemia inhibitory factor (LIF) to the media 
(Mummery et al. 2011a). 
Another source of pluripotent stem cells are primordial germ cells (PGCs) (Lensch et al. 2006). These 
cells are precursors of the later germ cells and are formed even before the gonads are present. During 
ontogeny the PGCs migrate through the developing embryo towards the newly formed gonads. During 
this migration they can be isolated and cultured in vitro (Mummery et al. 2011a). These PGC derived 
cells are called embryonic germ cells (EGCs). EGCs can proliferate indefinitely and give rise to cells of 
all germ layers plus the germline, however there are some differences between ESCs and EGCs such as 
cytokine requirements (Lensch et al. 2006) and their epigenetic state (Yu & Thomson 2008). EGCs but 
not ESCs retain certain epigenetic features of the PGCs, such as genome-wide demethylation and 
erasure of genomic imprints (Labosky et al. 1994; Tada et al. 1997). There is also the possibility to 
isolate pluripotent stem cells from the neonatal or adult testis, so called spermatogonial stem cells 
(Lensch et al. 2006). 
In 2006 Kazutoshi Takahashi and Shinya Yamanaka presented the possibility of generating induced 
pluripotent stem cells (iPSCs) from mouse embryonic and adult fibroblast cultures (Takahashi & 
Yamanaka 2006). Because iPSCs from adult tissues circumvent the ethical and legal issues of human 
embryonic stem cells, they are considered as a big hope for the development of stem cell based 
therapies (Kelly et al. 2011). A lot of progress has been achieved during the last years in terms of ways 
of reprogramming as well as characterization and potential use of iPSCs (Okita & Yamanaka 2010; 
Yamanaka & Blau 2010). Nevertheless I will not discuss this topic in more detail due to space 
limitations. 
 
1.1.1.3 Generation of mutant mice 
 
With today’s knowledge and techniques we are able to manipulate the genome of ESCs and transfer 
the cells into an early embryo where the ESCs contributes to the inner cell mass and thereby give rise 
to a genetically modified mouse (Nguyen & Xu 2008). The most common method to produce 
genetically manipulated mice is the generation of chimeras by injection of the ESCs into host 
blastocysts or morula stage embryos (Plück & Klasen 2009a). In addition there is the possibility to 
produce chimeras by the generation of aggregation embryos (Plück & Klasen 2009b). Chimeras are by 
definition composed of host and donor cells. All methods start with the isolation of embryos from 
superovulated donor mice and end with the transfer of the manipulated embryos to pseudo-pregnant 
recipients (Wells 2002). Although chimera production in general is relatively easy and efficient, 
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obtaining germline transmission can still be a difficult and tedious task, where the quality of the used 
ESCs is of high importance (Wells 2002). 
A great majority of all established mouse ESC lines is of male origin, thus these cells have 38 
autosomes plus an X and a Y chromosome. In XX ESCs both X chromosomes are active, which appears 
to be disadvantageous for ESC propagation (Smith 2001). During the establishment of an XX ESC line 
one of the two X chromosomes is lost very frequently (Zvetkova et al. 2005). If male ESCs are injected 
into a female blastocyst they may drive the embryo to develop into a male. This process is called sex 
conversion and leads to a distortion of the gender distribution by producing a high proportion of male 
offspring (Auerbach 2009).  
Using classical gene-targeting protocols, it takes about 1 year to establish a new mutant mouse line. 
By using the tetraploid complementation method it is possible to generate fertile adult mice, entirely 
derived from the donor ESCs (Wang et al. 1997). This is achieved by aggregating of ESCs with 
tetraploid four-cell stage embryos. While the ESCs are not or poorly able to form the extra-embryonic 
tissues, only the tetraploid cells are excluded from differentiating into embryonic tissues because of 
their aneuploidy. Thus, the embryo will be exclusively derived from the donor ESCs and the extra-
embryonic tissues will develop from the tetraploid cells (Wang et al. 1997). However, as this method is 
very inefficient, it is still not at the stage of providing an alternative in generating genetically modified 
mice compared to the chimeric route (Wells 2002). The “VelociMouse” method offers also a fast and 
efficient way to generate mutant mice (Poueymirou et al. 2007). To generate Veloci mice, laser-
assisted injection of ESCs into eight-cell stage embryos was found to efficiently yield F0 generation 
mice that are fully derived from the injected ESCs. This can be done with male or female, inbred or 
hybrid ESC lines. The generated F0 mice are healthy, exhibit highly efficient germline transmission and, 
most importantly, can be used directly for phenotypic analyses (Poueymirou et al. 2007).  
 
1.1.2 Aims of the project 
 
Breast cancer is the most common female cancer in the world, affecting about 10 % of women in 
industrialized countries (Szpirer & Szpirer 2007). Therefore we wanted to develop an in vivo breast 
cancer model by combining two innovative tools in order to rapidly assess the function of candidate 
cancer genes. Firstly, female F0 mice developing breast cancer will be generated by using female ESCs 
carrying an oncogene and laser-assisted 8-cell stage microinjection. In a second step, a targeting event 
will be performed in the ROSA26 locus of the oncogenic female ESCs to generate a switchable 
expression cassette, fused either to a Cre-controlled stop cassette or to the Tet-on/off system flanking 
shRNA sequences. Thus, different shRNAs can be inserted to knock down various candidate genes by 
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taking advantage of the endogenous RNAi machinery. Using these approaches, the effect of the 
inserted gene on breast cancer can be rapidly assayed in vivo (Figure 2). 
To accomplish these aims, a female ESC line was established, characterized for stemness qualities and 
the oncogene Polyoma Middle T (under control of the MMTV promoter) was targeted to these cells. 
Two independent clones were injected into blastocysts in order prove the stem cell function. In 
addition, to facilitate ROSA26 targeting, an exchange vector system was developed and its 
functionality demonstrated. The construct should allow the production of transgenic mice in an 
efficient, rapid and cost-effective manner. The advances achieved will significantly reduce time and 
costs associated with functional gene analysis in the mouse. 
 
 
Figure 2: Development of an in vivo breast cancer screening system using female ESC lines. [A] Double 
targeted ESCs carrying an oncogene and a shRNA construct are used for 8-cell injection, which allows analysis of 
the F0 offspring. 
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1.2 Results 
1.2.1 Generation of a novel ROSA26 inducible exchange vector system 
 
The exchange vector system was designed as a tool for rapid and efficient generation of inducible 
transgenic mouse models by targeting the ROSA26 locus. A detailed cloning procedure is summarized 
in the Materials and Methods section. The docking vector (DV; Figure 3A) contains 5’ and 3’ ROSA26 
homologous arms that flank a combined CMV (cytomegalovirus) and chicken β-actin promoter (CAG), 
a single loxP site, a promoterless hygromycin (hygro) resistance gene flanked by two attP sites and a 
reporter gene (IRES-EGFP-RpA). The exchange vector (EV) contains a promoterless βgeo cassette (lacZ 
combined with a neo resistance gene) followed by a stop signal, a loxP site and the gene of interest 
(GOI). This cassette is flanked by two attB sites (Figure 3B). 
 
 
A 
 
B 
 
C 
 
 
D 
 
Figure 3: Schematic drawing of the docking vector (DV) [A] the exchange vector (EV) [B] as well as the targeted 
locus upon ΦC31 integrase mediated exchange [C] and Cre mediated recombination [D]. ROSA26 5’ and 
ROSA26 3’ are the homologous parts of the genomic ROSA26 locus. CAG, coding sequence for the 
cytomegalovirus promoter fused with the chicken β-actin promoter; IRES-EGFP, internal ribosome entry site 
followed by the coding sequence for enhanced green fluorescent protein; βGEO-STOP, combined lacZ and neo 
resistance genes followed by a 3xpolyA-STOP cassette; GOI, gene of interest; RpA, rabbit polyA; black triangles, 
loxP sites; attB and attP sites, direct the recombination mediated by ΦC31 integrase; attL and attR sites remain 
after recombination, but are not further recognizable by ΦC31 integrase. 
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To introduce the DV construct into stem cells, male ESCs (clone A9) were electroporated and 33 hygro 
resistant ESC clones were picked and expanded for analysis. These clones were then screened for 
homologous recombination by Southern blot analysis and six correctly targeted clones (termed 
ROSA26-DV hereafter; 18 % efficiency) were identified (Figure 4A). One of the six ROSA26-DV cell lines 
was chosen and co-electroporated with the EV plasmid and the ΦC31 integrase. Upon co-transfection, 
an exchange between the attB/attP sites occurs, that could be detected via the conversion of hygro to 
neo resistance (Figure 4B, C). Only two neo resistant clones survived (ROSA26-DV-EV1 and 
ROSA26-DV-EV2), which could be explained by an inappropriate ratio of the EV and the ΦC31 
integrase. PCR analyses of clone ROSA26-DV-EV2 confirmed the presence of the neo gene and the loss 
of the hygro gene (Figure 4B). By contrast, PCR analysis of ROSA26-DV-EV1 resulted in detection of 
both resistance genes. The reason for that could be explained by random integration of the EV or a 
mixed population of cells. To further determine the antibiotic resistances, both cell lines were cultured 
in media supplied with either G418 (300 µg/ml) or hygromycin (150 µg/ml), respectively and cells 
were counted over a period of 3 days. The results of the growth curve are shown in Figure 4C. As 
expected, ROSA26-DV-EV2 cells died in hygromycin containing media and survived in G418 
supplemented media. Interestingly, ROSA26-DV-EV1 cells showed the same survival characteristics. 
Therefore one could assume that clone ROSA26-DV-EV1 also underwent correct cassette exchange. 
Next, ROSA26-DV-EV1 and ROSA26-DV-EV2 clones were analyzed for lacZ staining. As expected, all 
colonies of ROSA26-DV-EV1 as well as ROSA26-DV-EV2 turned blue upon substrate addition (Figure 
4D). The final step of the validation of the exchange vector system was to test the functionality of the 
loxP sites. Upon adenoviral delivery of Cre, the loxP flanked stop cassette is deleted and expression of 
the gene of interest (GOI) and EGFP is induced. EGFP expressing cells were indeed readily detected in 
Adeno-Cre transfected cells (Figure 4E). Taken together, we have successfully developed a ROSA26 
locus based exchange vector system that can be used to efficiently and rapidly target a gene of 
interest into a defined endogenous locus. 
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Figure 4: Generation and analysis of ROSA26-targeted ESCs. [A] Southern blot analysis of ROSA-DV targeted 
ESC clones to confirm integration of the DV construct via homologous recombination. Six clones were found to 
be targeted correctly (18 %).  Southern blots of 2 targeted and 2 non-targeted ESC clones are shown 
exemplarily. [B] The recombination between the DV and the EV could be verified by PCR for the neomycin (neo) 
and hygromycin (hygro) resistance cassettes, respectively. 1kb Plus DNA Ladder (Fermentas) is shown for size 
comparison. Hygro PCR product = 1.2kb; Neo PCR product = 500bp.  [C] Test of the antibiotic resistances by 
supplying the cells with media containing G418 or hygromycin, respectively. [D] Bluo-Gal staining of cultured 
ROSA-DV-EV cells indicates effective ΦC31 integrase mediated exchange. [E] Deletion of the stop cassette upon 
Cre-mediated recombination in ROSA-DV-EV cells. Fluorescence micrograph of EGFP-expressing cells is shown. 
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1.2.2 Characterization of the female A2 embryonic stem cells 
 
The female ESC line A2 (F1 129 x BL6) has been generated by 
Erwin Wagner (CNIO, Spain) and Anton Wutz (Wellcome Trust 
Centre for Stem Cell Research, Cambridge, UK). Eleven ESC lines 
were generated in total, five male (A1, A7, A8, A9 and A11) and 
six female (A2, A3, A4, A5, A6 and A10). The male or female 
karyotype of the ESC lines was proven via Southern blot analysis. 
As shown in Figure 5A, ESC clone A1 shows the male reference 
bands, whereas in clones A2 and A3 the Y chromosome was 
absent. 
Next, female XX A2 ESCs were further characterized for stem cell 
characteristics and pluripotency. One of the derived male ESC 
lines, A9, served as a reference for the stemness 
characterization. Macroscopically, female A2 cells form distinct 
colonies with well-defined borders similar to A9 cells (Figure 6A). 
Alkaline phosphatase (AP) staining, which is a classical stem cell 
marker (Wobus et al. 1984), showed blue colored colonies on a 
layer of unstained fibroblasts without any signs of differentiation 
(Figure 6B).  Many genes are known to be primarily expressed in 
undifferentiated stem cells. Among the most important stem cell 
markers are Oct3/4, Nanog and Sox2 (Imamura et al. 2006). Gene 
expression analysis of known stemness markers further revealed similar expression patterns between 
A2 and A9 ESC lines (Figure 6C).  
An assay for pluripotency is the generation of embryoid bodies (EBs). Pluripotent stem cells aggregate 
when cultured in suspension, resembling to some extent the earliest events in embryogenesis. The 
inner cells of the EBs start to differentiate and are supposed to be able to form all three germ layers 
(Keller 1995). Importantly, A2 cells indeed formed EB aggregates in suspension culture (Figure 7A). 
qPCR analyses further confirmed that marker genes specific for the endodermal (Brachyury, Afp2, Hnf, 
Foxa2), ectodermal (Sox2) and mesodermal (Sox2, Vimentin, Cdx2) lineage are expressed in EBs 
generated from the female ESCs (Figure 7B). The differences in expression levels between female A2 
and control male A9 ESCs are due to the fact that differentiation in EBs occurs stochastically towards 
one of the three germlayer lineages. These data show that the female ESC line A2 displays stem cell 
characteristics, comparable to the established control ESC line A9.  
A 
 
B 
Figure 5: Sex determination of newly 
derived ESC lines. [A] Southern blot 
detection of the Y chromosome in 
DNA samples of different ESC clones. 
A Y chromosome was detected in 
clone A1, whereas it could not be 
detected in clones A2 and A3. [B] The 
gel picture of the same experiment is 
shown to prove the successful 
loading and digesting of genomic 
DNA. Genomic DNA of the tail of a 
male mouse was used as a positive 
control (+). Both figures by courtesy 
of Uta Moehle-Steinlein. 
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B 
 
C 
 
Figure 6: Characterization of the female ESC line A2.  [A] Phase contrast micrograph of A2 and A9 
cells. A2 ESCs show a morphology typical for stem cells. [B] Alkaline phosphatase staining of A2 
and A9 cells indicates the undifferentiated state of both cell lines. [C] Similar levels of expression 
of stem cell markers in A2 and A9 cells. Expression of the β-actin gene was used to normalize the 
amount of the indicated transcripts. PCR reactions were done in duplicates. Data are shown as 
mean values.  
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A 
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Figure 7: Analysis of embryoid bodies (EBs) generated from female A2 ESCs. [A] Female A2 and 
male A9 cells aggregated to EBs when grown in suspension culture. [B] Gene expression analysis 
of EBs using qPCRs to detect genes specific for each of the three germ layers: endodermal 
(Brachyury, Afp2, Hnf, Foxa2), ectodermal (Sox2) and mesodermal (Sox2, Vimentin, Cdx2) lineage. 
Expression of the β-actin gene was used to normalize the amount of the transcripts. PCR reactions 
were done in duplicates. Data are shown as mean values. 
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1.2.3 Generation and characterization of MMTV-PyMT-IRESCRE-puro mice using female 
embryonic stem cells 
 
The most important proof of pluripotency of a cell line is to test its ability to generate chimeras that 
contribute to the germline. Additionally it was important to show, that A2 ESCs can be efficiently 
targeted. Therefore a MMTV-Polyoma Middle T (PyMT) oncogenic construct (Figure 8A) was delivered 
to A2 ESCs. MMTV-PyMT is known to be a potent oncogene inducing mammary tumors with a short 
latency and in a pregnancy-independent fashion in mice (Guy et al. 1992; Lin et al. 2003). Of note, the 
original construct was modified to a bicistronic construct where the oncogene PyMT and the IRES-CRE 
are under the control of the MMTV promoter (donation by William Muller). In addition, a PGK 
(phosphoglycerate kinase) promoter driven puromycin resistance selection cassette that can be 
excised by the Flp recombinase was added to generate the final vector MMTV-PyMT-IRESCRE-puro 
(Figure 8A). 
MMTV-PyMT-IRESCRE-puro was delivered to A2 ESCs by electroporation and ESCs were selected for 
puromycin resistance. Transgenic clones were identified by PCR and two positive low-copy number 
clones (A2/22 and A2/23) were selected and injected into C57BL/6 blastocysts to generate chimeras. 
Chimerism was assessed by coat color (Figure 8B). No live-born mice were derived from clone A2/23, 
whereas clone A2/22 yielded high percentages of chimeric mice (Figure 8C). The contribution of 
transgenic ESCs to the chimeras ranged from 10 to 100 %. High-percentage female chimeras were 
backcrossed to C57BL/6 males for germline transmission. The F1 generation was assayed by PCR for 
the presence of the transgenes PyMT and Cre (Figure 8D). The PCR results showed that germline 
transmission of the MMTV-PyMT-IRESCRE-puro was successful. Moreover, the transgene was 
inherited in a Mendelian fashion. 
Although PyMT is known to be a potent oncogene (Lin et al. 2003) no tumor development could be 
detected in viable female F1 transgenic mice up to the age of 9 months. Additionally, RNA of various 
tissues from 9-months old MMTV-PyMT-IRESCRE-puro transgenic female mice was prepared and PCR 
for PyMT expression was performed (Figure 9). Variable expression within the transgenic lines was 
observed ranging from strong expression in all tissues examined (mouse 1) to no detectable 
expression (mouse 3). In summary, we could demonstrate that the female ESC line A2 can be 
genetically manipulated and that it has the capability to contribute to the germline of chimeric mice. 
This opens new possibilities for usage of female ESCs for further genomic engineering approaches. 
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 C 
sex chimerism number of 
mice 
female 100 % 1 
female 95 % 5 
female 85 % 1 
female 10 % 1 
male 95 % 1 
 
D 
 
 
Figure 8: Generation of MMTV-PyMT transgenic mice from female A2 ESCs. [A] Schematic drawing of the PyMT 
transgene construct. PGK-PURO-pA encodes a phosphoglycerate kinase promoter (PGK), a puromycin resistance 
gene (PURO) and a terminal polyadenylation signal (pA). This cassette is flanked by FRT sites, which are 
recognition sites for the Flp recombinase. The remainder of the polycistronic plasmid codes for the mouse 
mammary tumor virus promoter (MMTV), the Polyoma Middle T oncogene (PyMT), the Cre recombinase with an 
internal ribosome entry site (IRES) and a SV40-virus polyadenylation signal. Black boxes, Frt sites. [B] Successful 
generation of chimeras as indicated by coat color. The contribution of transgenic ESCs to the mouse in the upper 
panel is estimated to be 10 %, whereas the mouse shown in the lower panel exhibits nearly 100 % chimerism. 
[C] A2 ESCs contributed to chimerism to different extents. [D] Verification of the presence of the transgene in 
the F1 generation by PCR detection of PyMT (P) and Cre (C) genes. 1kb Plus DNA Ladder (Fermentas). PyMT PCR 
product = 550 bp; Cre PCR product = 300 bp;  
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Figure 9: PCR analysis of MMTV-PyMT-IRESCRE-puro transgenic female mice. PyMT expression was detected in 
different tissues. PCR was performed on whole-organ lysates. A mosaic expression of the transgene was 
observed. PCR reactions were done in triplicates. n.d. = not determined. Plasmid DNA containing the 
MMTV-PyMT-IRESCRE-puro construct was used as a positive control. PyMT PCR product = 550 bp; 
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1.3 Discussion 
 
The aim of this part of the thesis was to develop a novel in vivo breast cancer model using female ESC 
lines. A so called exchange vector system for rapid and efficient exchange of transgenes or shRNAs in 
mouse ESCs was generated. This system should allow for rapid generation of mice bearing a transgene 
in their ROSA26 locus. Upon generation of a cell line carrying a docking vector (DV) in the ROSA26 
locus, such cells can be further targeted with different exchange vectors (EV), delivering the actual 
gene of interest.  Ideally, the gene of interest can be inserted into the EV plasmid by one single cloning 
step. Upon electroporation of the ROSA26-DV cell line with an EV construct and the ΦC31 integrase, 
the gene of interest is inserted into the ROSA26 locus. Furthermore, the functionality of all parts of the 
exchange vector system could be proven: the EV was integrated by ΦC31 integrase mediated cassette 
exchange, which altered the antibiotic resistance of the cell line as expected; the activity of the 
β-galactosidase was demonstrated and the stop cassette was shown not to be leaky, as the reporter 
gene located downstream was not expressed. Moreover, the βGEO-stop cassette was removed by an 
adenoviral approach which could be demonstrated by the expression of the reporter gene EGFP. To 
generate mice with a whole-body knock-in of the transgene, the stop cassette can be removed by 
in vitro Cre recombination. In addition, the cells can be used directly for generation of tissue specific or 
inducible knock-in of the gene of interest, followed by crossing the generated mice to Cre-transgenic 
lines. In terms of in vitro functionality, the exchange vector system is ready to be used for generating 
mice. The ability to generate germline competent chimeras has yet to be tested in order to exclude 
detrimental effects of the multiple manipulation steps. 
 
The stem cell characteristics of the female ESC line A2 were determined by different approaches such 
as alkaline phosphatase staining, gene expression analysis and EB formation. However, the most 
important prove of the stemness was the successful generation of chimeric mice. A2 cells were 
randomly targeted with an expression vector delivering the oncogenic construct MMTV-PyMT-
IRESCRE-puro and female chimeric mice were successfully derived. The chimerism ranged between 10 
and 95 %. Moreover, the transgene could be passed on the germline of the offspring. Although PyMT 
is known to act as a potent oncogene leading to early onset mammary hyperplasia and malignant 
progression associated with pulmonary metastases (Lin et al. 2003), no aberrant growth of mammary 
gland tissue could be detected in our mice so far. The site of integration as well as the gene dosage 
could account for this missing oncogenic potential. We detected expression of PyMT in various MMTV 
driven tissues, however, the gene dosage might be too low to lead to oncogenic transformation. The 
transgenic ESC clone used for blastocyst injection was chosen because of its low copy number, 
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whereas in the original publication the transgene was delivered to the embryo by pronuclear 
microinjection, thereby potentially integrating multiple copies into the genome (Guy et al. 1992). 
Indeed, in the publication by Guy et al. low amounts of middle T antigen RNA were mentioned not to 
be associated with apparent growth disturbance. Moreover, the transgene was expressed in a mosaic 
pattern. Mosaicism for MMTV-controlled transgenes has been reported previously (Wagner et al. 
2001). In the future, different transgenic founder lines have to be analyzed in more detail to identify 
mouse strains that can be used as breast cancer models. It might be also necessary to generate new 
chimeras by using an ESC clone with a higher copy number of the transgene to increase the gene 
dosage of PyMT. Nevertheless, the stem cell characteristics of the female ESC line A2 could be 
successfully proven and this cell line can now be used for further experiments. In the future, these 
ESCs will be delivered to 8-cell stage mouse embryos by laser-assisted injection (Poueymirou et al. 
2007) as this method yields F0 mice that are fully derived from the ESCs and can therefore be used 
directly for phenotyping, thereby greatly accelerating research. 
 
The ultimate ambition of these projects is to establish a novel tool for breast cancer research in mice. 
In contrast to some cancers, e.g. colon cancer, breast cancer comprises a spectrum of diseases that 
are genetically poorly defined. Various mouse models that harbor mutations in various signaling 
molecules and pathways that are implicated in different stages of tumor development have been 
generated to gain knowledge about the signaling events responsible for this disease (Watson 2002). 
Most mouse models of breast cancer take advantage of the MMTV promoter, yet other promoters are 
used as well (Taneja et al. 2009). Mouse strains used for breast cancer research are mostly designed to 
exhibit loss or gain of function mutations or amplifications of genes that have been found to be 
important in human breast cancers, as for example members of the EGFR family, cyclin D1 or Ras 
(Taneja et al. 2009). However, to further define the complex interactions of multiple genes in the 
process of oncogenesis, transgenic mice which harbor different genetic alterations have to be crossed 
with each other (Green et al. 2002). Our exchange vector system should facilitate this task. Double 
transgenic mice that express the randomly integrated PyMT construct as well as different shRNAs 
from the ROSA26 locus will be generated. The shRNAs will be designed to interfere with downstream 
targets of PyMT as well as with other molecules that possibly interact with PyMT driven malignant 
transformation. Comparison of the PyMT-only mice with PyMT-shRNA mice will help to understand 
the relevant signaling pathways. Furthermore, other oncogenes can be studied by this method as well. 
Taken together, two valuable tools for genetic research could be established. The combination of the 
exchange vector system with transgenic mice will open up many possibilities to greatly expand our 
understanding of the processes underlying the initiation, promotion and progression of breast cancer.  
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2 PART 2: Evaluation of the Role of MKK7 in Hepatitis 
 
2.1 Introduction 
 
The liver is the largest metabolic organ of the human body and performs crucial functions within the 
carbohydrate, protein and lipid metabolism (Faller & Schünke 2008). Moreover, it is important for 
detoxification of endogenous and exogenous substances (Faller & Schünke 2008). The 4 most common 
types of liver disease are cirrhosis, fatty liver, hepatitis and liver cancer (Sun & Karin 2008). Hepatitis 
and liver cancer are among the most serious public health problems worldwide. Hepatitis stands for 
“inflammation of the liver”, which can be caused by viral infections, toxins, alcohol and autoimmune 
syndromes (Sun & Karin 2008). In order to develop and improve therapies of these diseases, it is of 
great importance to understand the underlying pathogenic mechanisms at a molecular level. 
 
2.1.1 Mouse models of acute liver injury 
 
Over the last 40 years a lot of knowledge has been gained concerning the understanding and 
treatment of acute hepatic failure (AHF). This progress is largely due to the use of different animal 
models that reflect the clinical, biochemical and histological pattern of the syndrome seen in man 
(Rahman & Hodgson 2000). The most common species used for hepatitis research are pig, dog, rabbit, 
rat and mouse (Tuñón et al. 2009), but each model often only reflects a particular aspect of AHF 
(Rahman & Hodgson 2000). Small animals as mouse and rat offer ways to study the molecular events 
underlying AHF but for the development of artificial liver support systems larger animals as pig and 
dog are being used (Tuñón et al. 2009). 
In 1991 Terblanche and Hickman suggested 6 main criteria for a suitable AHF animal model 
(Terblanche & Hickman 1991; Tuñón et al. 2009; Rahman & Hodgson 2000): 
• Reversibility – suitable treatment may reverse and improve survival 
• Reproducibility – reproducible end-points are required to standardize the model 
• Death from liver failure – should reflect the human clinical pattern and death should be a 
direct result of the insult to the liver 
• Therapeutic window – time for treatment should be available between insult and death to be 
assessed for its effect 
• Adequate animal size – size large enough to allow blood and tissue analysis to take place 
serially 
• Minimum hazard to personnel – minimum risk for operators and associated staff 
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2.1.1.1 A surgical model – Partial hepatectomy 
 
The liver has the unique ability to repair itself after suffering loss of tissue mass from surgical resection 
or pathogenic and toxic factors (Fausto 2000). This regeneration is achieved by the re-entry of 
quiescent hepatocytes into the cell cycle (Mitchell et al. 2005). In response to liver injury, hepatocytes 
begin to grow to compensate for the lost cells and stop growing when the liver mass reaches within 
10 % of the original liver mass (H. Cao et al. 2009). Partial hepatectomy (PH) provides a unique tool to 
study the regulation of proliferation and organ regeneration in vivo (Mitchell & Willenbring 2008). 
Two-thirds partial hepatectomy (70%) is the most studied model of liver regeneration in mice (Cao et 
al. 2009). Mice are able to regenerate their original liver mass within 2 weeks following 65-70 % PH 
(Cao et al. 2009). 90 % PH is considered to be the upper limit for a liver regeneration model in mice, as 
larger resections produce lethal hepatic failure (Tuñón et al. 2009). In humans liver regeneration can 
be also observed in split-liver transplantation, where the size of the donor’s liver doubles within 7 
days, and the recipient’s between 7-14 days after surgery (Cao et al. 2009). The main disadvantages of 
this surgical method are the poor reproducibility and the reliance on surgical expertise. Another 
drawback is the inability of the model to recreate the inflammatory milieu that exists in acute liver 
failure (Newsome et al. 2000). 
 
2.1.1.2 Chemical models 
 
Galactosamine 
D-galactosamine (GalN) is a selective hepatotoxin which, when metabolized via the galactose pathway 
in the liver, causes serious metabolic alterations and hepatic necrosis (Tuñón et al. 2009; Newsome et 
al. 2000). GalN blocks the transcriptional activity of nuclear factor-κB (NF-κB) (Ni et al. 2008). NF-κB is 
activated by tumor necrosis factor α (TNFα) and acts as a suppressor of the apoptotic effects of TNFα 
(Kucharczak et al. 2003). GalN is commonly used in murine models of acute liver damage in 
combination with Concanavalin A or lipopolysaccharide (LPS) (Ni et al. 2008). 
 
Concanavalin A 
An initial event in the pathophysiology of a variety of liver diseases is the activation of T lymphocytes, 
which in turn interact with macrophages, leading to a release of proinflammatory cytokines such as 
TNFα and interferon gamma (IFNγ) (Künstle et al. 1999). Upon treatment with the T-cell mitogen 
Concanavalin A (ConA), TNFα and other hepatotoxic cytokines are secreted by T lymphocytes. ConA 
alone causes a mild liver injury that is followed by regeneration (Ni et al. 2008). Hepatocyte death is 
evident with the increased liver enzymes in the blood (Ni et al. 2008). The combination of ConA with 
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GalN leads to a more severe and irreversible liver damage with high mortality. In this model, a potent 
activation of apoptosis with significantly increased caspase activities is observed (Ni et al. 2008).  
 
Lipopolysaccharide (LPS) 
Another way of inducing TNFα is by treatment with LPS which stimulates resident macrophages in the 
liver, the Kupffer’s cells (Chensue et al. 1991). Administration of LPS to rodents leads to endotoxic 
shock (Morrison & Ryan 1987). To provoke LPS-induced liver damage without affecting other organs, 
LPS is injected at subtoxic amounts into GalN-sensitized animals (Mizuhara et al. 1994). Combined 
treatment with LPS and GalN leads to significant apoptosis of hepatocytes and irreversible liver 
damage with a high mortality (Ni et al. 2008). 
 
Acetaminophen 
The commonly used drug acetaminophen (paracetamol) is known to be able to produce hepatic 
damage. Acetaminophen overdoses cause a large proportion of cases of AHF in Western countries, 
whereas the main causes of AHF in developing countries are viral illnesses, particularly infections with 
hepatitis B and E viruses (Lee 2008). The toxic effects of acetaminophen are dose-dependent 
(Newsome et al. 2000) and can be increased by fasting, cytochrome P-450 inducing drugs and alcohol 
consumption (Whitcomb & Block 1994). The hepatic detoxifying metabolism of acetaminophen is 
related to species and age, therefore different studies on this drug produce greatly heterogeneous 
results (Gregus et al. 1988). The major disadvantages of acetaminophen models are poor 
reproducibility and the varying time-lag between damage induction and death of the research animals 
(Newsome et al. 2000).  
 
Carbon tetrachloride 
Carbon tetrachloride (CCl4) is a hepatotoxin that causes acute liver injury (Tuñón et al. 2009). It has 
also been widely used to induce chronic liver damage by repeated administration of low doses. 
Injection of CCl4 can serve as a model for hepatic cirrhosis, liver fibrosis and cancer (Tuñón et al. 2009; 
Weiler-Normann et al. 2007). In the liver, CCl3 radicals are formed by cytochrome P450 isozymes 
(Wong et al. 1998) which then induce hepatocyte damage and activation of hepatic stellate cells, 
leading to the production of extracellular matrix (Weiler-Normann et al. 2007). 
 
2.1.1.3 Viral models 
 
Although viral hepatitis is one of the main causes of AHF (Bernuau et al. 1986), the use of infective 
agents to develop animal models of AHF has been rather unsuccessful until now. There have been 
23 
 
studies with transgenic mice overexpressing virus B hepatitis proteins and with mice infected with 
murine hepatitis virus strain 3 (MHV-3), which shed some light on virus induced AHF mechanisms 
(Tuñón et al. 2009). As human HBV and HCV only infect humans and chimpanzees (Chayama et al. 
2011), the analysis of both viruses has long been hampered by the absence of a small animal model. 
Transgenic mice that express HBV-DNA and export virus particles into the serum have been used to 
study antiviral agents. But as the viral life cycle is not established in this model, it is inappropriate to 
investigate the whole spectrum of HBV infections and the related hepatitis (Chayama et al. 2011). In 
recent years progress has been made by the development of human hepatocyte chimeric mice that 
are susceptible to HBV and HCV infections (Tsuge et al. 2005; Hiraga et al. 2007). 
 
2.1.2 TNF-induced signaling in hepatocytes 
 
The main mediators of liver inflammation are cytokines such as TNFα, interleukin-1β (IL-1β) or IFNγ, as 
well as oxidative stress radicals and bile acids (Jaeschke et al. 2002). Exposure to these agents will 
eventually cause hepatocyte cell death, which can contribute to acute liver injuries. On the other hand 
insufficient apoptosis of hepatocytes and unrestrained proliferation within the context of chronic 
inflammation can promote the development of liver cancer (Pikarsky et al. 2004). One of the earliest 
events in hepatic inflammation is the induction of TNFα (Mizuhara et al. 1994), which then triggers a 
cascade of other cytokines that cooperate in recruiting inflammatory cells (Ramadori et al. 2008), 
killing hepatocytes and initiating a wound-healing response (Bradley 2008; Wullaert et al. 2007). 
Although TNFα is involved in the pathology of various inflammatory liver diseases, it was also shown 
that TNF is necessary for liver regeneration, for instance following partial hepatectomy (Akerman et al. 
1992). Thus, the proinflammatory cytokine TNFα acts as a key regulator of the crucial balance 
between hepatocyte proliferation and hepatocyte cell death (Wullaert et al. 2007).  
TNFα can be bound by two plasma membrane receptors, TNF-receptor 1 (TNF-R1) and TNF-R2, where 
TNF-R1 is the main receptor for soluble TNF and TNF-R2 generally mediates the effects of the 
membrane-bound TNF precursor (Maeda et al. 2003). The majority of biological effects in the liver is 
mediated by TNF-R1 but it was also shown, that TNF-R2 can play a crucial role in certain conditions 
(Küsters et al. 1997). Pathways that can be induced by TNF-R1 include the activation of the 
transcription factor nuclear factor-κB (NF-κB) (Cao et al. 1999), initiation of MAPK cascades as well as 
cell death (Micheau & Tschopp 2003). This broad range of different signaling pathways initiated by 
TNF-R1 is accomplished by the recruitment of various adapter proteins to its cytoplasmic part (Liu et 
al. 1996; Wullaert et al. 2007). TNFα signaling starts with the rapid formation of complex I which 
consists of TNF-R-associated death domain (TRADD), TNF-R-associated factor 2 (TRAF2) and receptor 
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interacting protein 1 (RIP1) (Chang et al. 2006). This complex then further recruits TGFβ-activated 
kinase 1 (TAK1) which then activates NF-κB signaling. NF-κB target genes are often associated with cell 
survival and proliferation (Hayden et al. 2006). As TAK1 is a member of the MAP3K family it also 
activates p38 and JNK cascades (Inokuchi et al. 2010). Subsequently by dissociation of complex I from 
the receptor and recruitment of Fas-associated death domain (FADD) and pro-caspase-8, signaling 
complex II is formed (Micheau & Tschopp 2003). The clustering of pro-caspase-8 allows its 
autoactivation and the thereby activated caspase-8 is then able to proteolytically activate several 
effector caspases (Juo et al. 1998; Yang et al. 1998). However, if NF-κB has been activated during 
complex I formation, it prevents caspase-8 activation by complex II through induction of c-FLIP. c-FLIP 
is an adapter protein with a pseudo-caspase domain, which specifically inhibits caspase-8 (Chang et al. 
2006). In cells that lack substantial NF-κB activity, formation of complex II results in caspase-8 
activation and ultimately leads to apoptosis (Chang et al. 2006). In the case of hepatocytes, however, a 
second pathway is required for TNF-induced apoptosis, which involves an abrupt increase of the 
permeability of the inner mitochondrial membrane and relase of cytochrome c (Bradham et al. 1998). 
 
2.1.2.1 MAP kinase signaling cascades 
 
Cells have to be able to respond to extracellular stimuli and environmental changes in order to survive 
and perform their functions. This response is often mediated by the activation of transcription factors, 
which then induce the appropriate cellular process (Keshet & Seger 2010). As most extracellular 
agents cannot cross the plasma membrane, intracellular signaling pathways transmit the signals to 
various cytoplasmic and nuclear targets. Such pathways often act by sequential phosphorylation 
events called protein kinase cascades. This type of signaling mechanism is used by the mitogen-
activated protein kinase (MAPK) signaling cascades, which will be described in the following sections 
(Keshet & Seger 2010). 
MAPK signal transduction pathways are highly conserved from yeast to humans (Avruch 2007) and are 
among the most widely used activation pathways of eukaryotic cell regulation (Kyriakis & Avruch 
2001). Different MAPK pathways are utilized by all eukaryotic cells to respond coordinately to multiple 
and divergent inputs. In mammals MAPKs can be activated by a broad spectrum of different stimuli, 
which include hormones, growth factors, inflammatory cytokines and environmental stresses such as 
radiation, osmotic shock or ischemic injury (Krishna & Narang 2008). Cells detect those signals through 
different receptor families that are coupled to MAPK pathways, such as receptor tyrosine kinases 
(RTKs) or G protein-coupled receptors (GPCRs) (Goldsmith & Dhanasekaran 2007; McKay & Morrison 
2007). Many cellular activities can be regulated by those pathways, for example gene expression, cell 
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cycle progression and cell growth, cellular metabolism, motility or apoptosis (Johnson & Lapadat 
2002). Today about 70 genes are known that encode for almost 200 distinct components that 
compose the MAPK system. This multiplicity is needed to facilitate the specificity and tight regulation, 
which are hallmarks of these cascades (Keshet & Seger 2010). 
The most typical feature of the architecture of all MAPK pathways is the central three-tiered kinase 
cascade. This cascade consists of three sequentially acting kinases: a MAPK, a MAPK kinase (MAPKK, 
MAP2K, MKK) and a MAPK kinase kinase (MAPKKK, MAP3K, MEKK) (Ferrell 1996). MAP3Ks are Ser/Thr 
kinases which are activated by upstream Ras and Rho family GTPases in response to an extracellular 
stimulus (Kyriakis & Avruch 2001). MAP3Ks in turn phosphorylate and thereby activate the 
downstream MAP2Ks. These kinases are dual specificity kinases, which means that they can 
phosphorylate MAPKs on threonine and tyrosine on a conserved Thr-X-Tyr motif in order to activate 
them (Dhanasekaran & Premkumar 1998). Activated MAPKs are then able to phosphorylate their 
target substrates on serine or threonine residues only if those are followed by proline. Their 
substrates can be transcription factors, other kinases (MAPK activated kinases, MKs) or proteins like 
cytoskeletal proteins (Krishna & Narang 2008). Important mammamalian MAPK cascades are 
extracellular signal-regulated kinase 1 and 2 (ERK1/2), c-Jun N-terminal kinase 1–3 (JNK1–3), p38MAPK 
α, β, γ, δ (p38α–δ) and ERK5 (Qi & Elion 2005). Each of these cascades can regulate distinct but 
sometimes overlapping cellular processes. Misregulation of this highly sophisticated network often 
leads to diseases such as cancer, diabetes or inflammation (Keshet & Seger 2010). 
 
2.1.2.2 MKK7 
 
MKK4 and MKK7 are MAPK kinases that are crucial for the transduction of signals to the downstream 
stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) as they are the only known 
molecules that directly activate JNK (Tournier et al. 1997; Nishina et al. 1997). Both, MKK4 and MKK7 
are activated in response to a variety of cellular stresses, including UV and γ-irradiation, 
hyperosmolarity, T cell receptor stimulation or inflammatory cytokines (Yao et al. 1997). The activity of 
MKK4 and MKK7 is increased following phosphorylation at serine and threonine residues within a 
Ser-X-Ala-Lys-Thr motif in their activation loops by multiple MAPK kinase kinases, including MEKK1-4, 
members of the mixed lineage kinase (MLK) family, apoptosis signal-regulated kinase 1 (ASK1) and 
TGFβ-activated kinase 1 (TAK1) (Wang et al. 2007). Activated MKK4 and MKK7 in turn activate JNK by 
dual phosphorylation of its Thr-Pro-Tyr motif. Although both MAPK kinases are dual specificity kinases, 
MKK4 preferentially phosphorylates the tyrosine residue, whereas MKK7 phosphorylates the 
threonine residue within the Thr-Pro-Tyr motif (Fleming et al. 2000). In vitro and in vivo studies 
support the model of a synergistic activation of JNK by both MKK4 and MKK7 (Asaoka & Nishina 2010). 
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The murine gene encoding MKK7 encodes 14 exons that can be alternatively spliced to generate 
different isoforms (Tournier et al. 1999). There are three possible N-termini (α, β and γ isoforms) as 
well as two different C-termini (1 and 2 isoforms). The physiological relevance of different MKK7 
isoforms remains to be proven and elucidated (Asaoka & Nishina 2010). In the adult mouse MKK4 and 
MKK7 are ubiquitously expressed in all organs, however there are notable differences in the pattern of 
expression during embryogenesis between MKK4 and MKK7, indicating their distinct functions in 
development (Wang et al. 2007). Mkk7+/- mice appear normal and fertile without any obvious defects. 
Mkk7-/- embryos die between E11.5 and E13.5 of severe anemia associated with impaired 
hepatogenesis (Wada et al. 2004). The same is seen for mkk4-/- fetuses which additionally show severe 
hemorrhage in the region of the liver at E12.5 associated with increased apoptosis (Nishina et al. 1999; 
Wang et al. 2007). Mouse embryonic fibroblasts (MEFs) derived from mkk7-/- embryos show decreased 
proliferation from passage 4-5 onwards plus premature senescence. JNK activation is impaired at the 
basal level as well as upon stimulation and overexpression of the second JNK activating kinase MKK4 
cannot substitute for the loss of MKK7 (Wada et al. 2004). Moreover, the activation of JNK in response 
to proinflammatory stimuli as TNFα and IL-1 is almost completely lost in mkk7-/- cells but only reduced 
by about 50 % in mkk4-/- cells (Tournier et al. 2001). These data indicate that while MKK4 is required 
for optimal JNK activation, MKK7 is essential for the stimulation of JNK activity by proinflammatory 
cytokines (Tournier et al. 2001). 
 
2.1.2.3 JNK 
 
Two major MAPK pathways are the c-Jun NH2-terminal kinase (JNK) and the p38 MAPK pathways, 
which are both termed stress-activated protein kinase (SAPK) pathways as they are activated by 
various genotoxic and environmental stresses (Hibi et al. 1993; Han et al. 1994; Wagner & Nebreda 
2009). These pathways have important functions in inflammation and tissue homeostasis by 
controlling cell proliferation, differentiation and survival of specific cell types (Kyriakis & Avruch 2001).  
Three genes are encoding JNK proteins, mapk8 encodes JNK1, mapk9 encodes JNK2 and mapk10 
encodes JNK3. All genes are alternatively spliced giving rise to at least ten isoforms (Gupta et al. 1996). 
JNK signaling is regulated by recognition of conserved motifs between MKKKs and MKKs as well as 
between MKKs and MAPKs and by scaffold proteins that assemble the MKKK-MKK-MAPK module in 
larger protein complexes (Mooney & Whitmarsh 2004). At least 20 MAPK kinase kinases are known of 
which at least 14 activate the MKK4/MKK7-JNK axis, demonstrating the importance of JNK pathways in 
the cellular response to external stimuli (Johnson & Nakamura 2007). 
27 
 
Depending on stimulus and cell type, JNKs can phosphorylate a number of activator protein-1 (AP-1) 
components, including c-Jun, JunB, JunD and activating transcription factor 2 (ATF2) (Bode & Dong 
2007), thereby regulating various target genes that contain AP-1 binding sites, including genes that 
control cell cycle, survival, apoptosis, metalloproteinases and nuclear hormone receptors (Wagner & 
Nebreda 2009). In addition to transcription factors JNKs can also phosphorylate non-transcription 
factors such as Bcl-2, Bcl-xL, paxillin and MAP2 (Nishina et al. 2004). Apart from their kinase activity 
JNK proteins also function to target some of their own substrates for degradation. For instance, c-Jun 
is marked for ubiquitinylation and subsequent degradation when associated with inactive JNK (Bode & 
Dong 2007). Depending on stimulus and the strength and duration of JNK activation, the cellular 
response has diverse outcomes, which range from induction of apoptosis to increased survival 
(Wagner & Nebreda 2009). For instance, whereas the early transient phase of JNK activation (<1 h) 
corresponds to cell survival, the later and more sustained phase of JNK activation (1-6 h) mediates 
TNFα-dependent apoptosis (Ventura et al. 2006). 
 
2.1.2.4 AP-1 transcriptional complexes 
 
The AP-1 transcription factors are dimeric complexes that are composed of members of the Jun, Fos, 
ATF and MAF (musculoaponeurotic fibrosarcoma) protein families (Curran & Franza 1988; Kataoka et 
al. 1994). AP-1 complexes can be formed by many different combinations of hetero- and homodimers, 
and these combinations determine the transcriptional targets that are regulated (Hai & Curran 1991). 
c-Jun appears to be especially important for hepatocytes, although it is expressed in a variety of 
different tissues (Eferl et al. 2003). For instance, it has been shown that in chimeric mice generated 
from c-Jun deficient ESCs, ESC derivatives can be found in all organs but were absent among 
hepatocytes (Eferl et al. 2003). The function of c-Jun in hepatocytes seems to depend on their 
differentiation stage, as fetal hepatocytes require c-Jun for cell survival, whereas differentiated 
hepatocytes rather require it for cell cycle progression (Eferl et al. 2003). The importance of c-Jun in 
the liver is also demonstrated by the fact that it is strongly expressed in human livers with severe 
acute hepatitis whereas livers without signs of inflammation express low levels of c-Jun (Hasselblatt et 
al. 2007). c-Jun expression in inflamed livers is predominately localized to hepatocytes rather than 
inflammatory cells. Furthermore, it was shown that liver-specific c-Jun deletion leads to impaired liver 
regeneration following PH (Behrens et al. 2002). Thus, c-Jun is a key regulator of hepatocyte 
proliferation (Stepniak et al. 2006). 
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2.1.3 Aims of the project 
 
Over the last years and decades, multiple studies have addressed the role of TNF-MKK7-JNK pathway 
in liver inflammation (Figure 10). In 2003 Maeda et al. stated that ConA-induced liver damage is 
considerably reduced in Jnk1-/- as well as in Jnk2-/- single knockout mice (Maeda et al. 2003). However 
in a publication from 2009 by the group of Roger J. Davis this could not be confirmed. They detected 
similar hepatic damage in wild-type as in Jnk1 or Jnk2 single knockout mice. Moreover, they showed 
that Mx 1-Cre+ Jnk1f/f Jnk2-/- mice exhibit a strong protection against ConA induced hepatitis. In 
addition they could find the same protection using the LPS/GalN hepatitis model. This protection 
against hepatitis was found to be associated with reduced mortality, reduced serum transaminase 
activity as well as decreased expression of AP1-related genes and Tnfα mRNA in the liver and 
decreased amounts of serum TNFα (Das et al. 2009). The key conclusion of this publication was that 
JNK is not required for TNFα-mediated death of hepatocytes but JNK is essential for the expression of 
TNFα by hematopoietic cells that promote hepatitis (Das et al. 2009). In 2007 Hasselblatt et al. 
published that mice lacking c-Jun in hepatocytes display increased liver cell death and mortality upon 
ConA injection. This phenotype was caused by the impaired expression of nitric oxide synthase 2 
(Nos2) and a thereby reduced production of nitric oxide (NO), a hepatoprotective agent (Hasselblatt et 
al. 2007). The aim of my project was to analyze the potential function of MKK7 in immune cells or in 
liver cells using the LPS/GalN acute hepatitis model (Figure 10). 
 
 
Figure 10: Different components of the MKK7-JNK pathway have been examined in the context of liver 
injury. The Figure gives an overview of the different outcomes in liver injury models when one or another 
player of the same signaling cascade is genetically inactivated. 1,2 (Das et al. 2009); 3 (Hasselblatt et al. 2007) 
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2.2 Results 
 
2.2.1 Liver and hematopoietic specific deletion of MKK7 
 
To test the role of MKK7 in the LPS/GalN liver injury model, we crossed MKK7 fl/fl mice to either Alfp-
Cre or Mx1-Cre transgenic mice. To achieve a functional knockout of MKK7, exons 3 to 11 are deleted 
upon Cre recombination (Schramek et al. 2011). In the Alfp-Cre construct the Cre recombinase is 
under the control of both the mouse albumin regulatory elements (promoter and enhancer) and the 
α-fetoprotein (AFP) enhancers, thus mimicking the genomic organization of the mouse albumin gene 
(Kellendonk et al. 2000). In mice and other mammals the albumin gene is located upstream of the AFP 
gene and its expression is thought to be influenced by the AFP enhancers located between both genes 
(Kellendonk et al. 2000). In mice the expression of the albumin gene starts during embryogenesis 
shortly after the appearance of the liver bud (E9.5) (Kellendonk et al. 2000).  
Loss of MKK7 protein was determined by Western blot analysis in liver lysates of Alfp-Cre MKK7Δ/Δ 
mice (termed MKK7ΔAlfp hereafter), Alfp-Cre MKK7Δ/+ mice (termed MKK7Δ/+Alfp hereafter) and control 
MKK7fl/fl mice (termed MKK7Ctrl hereafter) (Figure 
11). Of note, MKK7 protein was still detectable at 
low levels in MKK7ΔAlfp livers. This is licit as the Alfp-
Cre transgene is expressed only in hepatocytes and 
biliary duct cells but not in nonepithelial cells of the 
liver, such as endothelial and Kupffer cells 
(Kellendonk et al. 2000). 
In Mx1-Cre mice the expression of the Cre 
recombinase transgene is controlled by the 
promoter of the mouse Mx1 gene (Kühn et al. 
1995). Mx1 is part of the defense to viral infections 
and remains silent in healthy mice. Upon 
application of interferon α (IFN-α) or IFN-β or of 
synthetic double-stranded RNA (polyinosinic-polycytidylic acid – poly(I:C)) the promoter can be 
transiently activated to high amounts of transcription in various tissues (Kühn et al. 1995). Mx1-Cre 
deletes, amongst others in the liver and the hematopoietic system (Kühn et al. 1995). Western blot 
confirmed no detectable MKK7 expression in Mx1-Cre MKK7Δ/Δ (termed MKK7ΔMx1 hereafter) liver 
samples following poly(I:C) injections (3 injections, 13 mg/kg) (Figure 11). 
  
 
Figure 11: Deletion of MKK7 in the liver. Deletion 
efficiency in MKK7ΔAlfp and MKK7ΔMx1 mice was 
detected by Western blot analysis of whole liver 
lysates. MKK7ΔAlfp mice (lanes 1-3), MKK7ΔMx1 mice 
(lanes 6-8) and MKK7Ctrl mice (lanes 4, 5, 9, 10). 
MKK7 protein is strongly reduced in MKK7ΔAlfp livers 
and not detectable in MKK7ΔMx1 livers. 
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2.2.2 Hepatocyte-specific deletion of MKK7 does not protect against LPS/GalN induced 
hepatitis 
 
Injection of LPS/GalN induces severe apoptosis of hepatocytes and irreversible liver damage with high 
mortality (Ni et al. 2008). At a lethal dose of LPS/GalN (10 µg/kg LPS, 1 g/kg GalN) mice die within 6 to 
8 hours after injection. In Figure 12A the survival curves of LPS/GalN treated mice of different 
genotypes are shown. We classified end points according to the following symptoms: ruffled fur, 
partly-closed eyes, no spontaneous movements, no erecting after being put on the side. When these 
symptoms were observed, mice were euthanized for ethical reasons. Overall, the survival curves 
(Figure 12A) indicate that all genotypes are equally susceptible to LPS/GalN induced liver injury.  
Liver injury can be detected by measurement of serum ALT (alanine aminotransferase) activity levels. 
A similar, but less specific marker is AST (aspartate aminotransferase) in the serum (Ozer et al. 2008). 
Both serum transaminases play important roles in amino acid metabolism and gluconeogenesis (Ozer 
et al. 2008). ALT is primarily expressed in the liver and to a lower extent in skeletal muscle and heart, 
whereas AST is expressed in heart, brain, skeletal muscle and liver. Damaged cells release their 
contents into the extracellular space where they ultimately enter blood circulation (Ozer et al. 2008). 
No increase in ALT or AST levels was detectable two hours, whereas a strong induction of ALT and AST 
occured 8 hours after LPS/GalN injection (Figures 12B and 12C). The induction of AST levels was found 
to be similar in MKK7Ctrl and MKK7ΔAlfp animals. Taken together, the levels of ALT and AST in the serum 
upon LPS/GalN treatment were found to be equal in MKK7ΔAlfp and MKK7Ctrl mice, indicating a similar 
liver injury. 
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Figure 12: Survival curves and ALT/AST levels upon LPS/GalN treatment in MKK7ΔAlfp mice. [A] Survival curves 
of Alfp-Cre MKK7Δ/Δ mice (MKK7ΔAlfp), Alfp-Cre MKK7Δ/+ mice (MKK7Δ/+Alfp) and control MKK7fl/fl mice 
(MKK7Ctrl) upon treatment with LPS/GalN (10µg/kg; 1g/kg). n = 8. To detect liver injury, serum ALT [B] and serum 
AST [C] activities were determined. Mice were sacrificed after 2 and 8 hours after LPS/GalN challenge. The 
baseline (time 0) was set by analysis of PBS-treated mice. PBS MKK7Ctrl n = 4; PBS MKK7ΔAlfp n = 4; 
LPS 2 hours MKK7Ctrl n = 7; LPS 2 hours MKK7ΔAlfp n = 6; LPS 8 hours MKK7Ctrl n = 8; LPS 8 hours MKK7ΔAlfp n = 8; 
Data are shown as mean values ± SEM; T-test: not significant. U/l = units per liter. SEM = standard error of the 
mean. 
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We next monitored liver damage of LPS/GalN treated mice histologically. PBS-treated mice showed 
normal, healthy liver architecture (Figure 13, upper panels), whereas in LPS/GalN treated animals 
massive bleeding into the parenchyma was observed throughout the whole organ (Figure 13, lower 
panels). The degree of tissue damage was found to be similar between MKK7Ctrl and MKK7ΔAlfp mice. To 
specifically determine the apoptosis rate, TUNEL stainings of liver sections were performed (Figure 
14A). For the quantification of apoptotic cells a computed algorithm was established with support of 
the BioOptics department at IMBA/IMP. In brief, this program is able to count and distinguish 
between blue dots (DAPI-stained nuclei; one dot is equal to one cell) and green dots (one dot is equal 
to one apoptotic cell stained by the TUNEL reaction). The quotient of apoptotic cells to all cells 
indicates the percentage of apoptosis. As shown in Figure 14B apoptosis upon LPS/GalN treatment 
was similar in the livers of MKK7Δ/+Alfp and MKK7ΔAlfp mice. Thus, treatment with LPS/GalN showed 
similar hepatic damage, as measured by survival, serum transaminase levels, histological analyses and 
apoptotic rates, suggesting that hepatocyte specific MKK7 deficiency does not confer protection in this 
liver injury model. 
 
 
 Figure 13: Histological analysis of livers upon LPS/GalN treatment. Representative H&E stainings of 
liver sections of PBS or LPS/GalN (10µg/kg; 1g/kg) treated MKK7Δ/+Alfp and MKK7ΔAlfp mice are 
shown. Massive bleeding was seen in LPS/GalN treated livers of MKK7Δ/+Alfp and MKK7ΔAlfp mice (see 
inserts). Samples were taken 8 hours after injections. 
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Figure 14: Evaluation of apoptosis by TUNEL staining. [A] TUNEL stainings of liver sections to determine the 
extent of apoptosis in mice that received PBS and mice challenged with LPS/GalN. Apoptotic cells are stained 
green, all nuclei are stained blue (DAPI). [B] Quantification of apoptotic cells: Average proportions of apoptotic 
cells in 3 liver sections of 4 MKK7Δ/+Alfp livers and 4 MKK7ΔAlfp livers were calculated. Total cell numbers were 
determined by DAPI staining. Data are shown as mean ratios ± SEM of apoptotic (green) cells divided by non-
apoptotic (blue) cells. PBS n = 1; LPS n = 4. Samples were taken 8 hours after PBS respectively LPS/GalN 
injections (10µg/kg; 1g/kg). SEM = standard error of the mean. 
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2.2.3 Gene  expression and cytokine analysis in MKK7ΔAlfp livers 
 
To elucidate expression of signaling molecules in the liver upon LPS/GalN challenge, qPCR analyses 
were performed 2 and 8 hours after LPS/GalN injection. In MKK7Ctrl mice expression of Mkk7 was 
down-regulated 2 hours after the injection and was slightly increased at 8 hours (Figure 15). By 
contrast, Gadd45β, a specific inhibitor of MKK7 (Papa et al. 2004), showed the opposite expression 
pattern, as Gadd45β mRNA was strongly induced after 2 hours and down-regulated to basal levels 
after 8 hours. Importantly, there was no difference in Gadd45β induction and expression between 
MKK7Ctrl and MKK7ΔAlfp liver samples. 
The MKK7-JNK stress pathway regulates gene transcription through phosphorylation of multiple 
transcription factors, including c-Jun (Davis 2000). The basal expression of c-Jun and JunB, but not 
JunD mRNA was increased in MKK7Ctrl livers compared to MKK7ΔAlfp livers, albeit these differences were 
statistically not significant. All three AP-1 members were down-regulated 2 hours upon LPS/GalN 
treatment in the livers of MKK7Ctrl mice, whereas mRNA levels remained unchanged within the first 
two hours in MKK7ΔAlfp livers. Two hours after LPS/GalN challenge the level of JunD mRNA was 
significantly higher in MKK7ΔAlfp samples than in control samples (p-value 0.036). Between 2 and 8 
hours c-Jun and JunB mRNA levels increased in livers of both genotypes. The expression level of JunD 
mRNA after 8 hours was elevated compared to the 2-hours time point only in MKK7Ctrl samples. The 
amount of JunD mRNA in MKK7ΔAlfp livers remained unchanged throughout all examined time points. 
As Tnfα expression is critical for the development of liver injury in the LPS/GalN model (Wullaert et al. 
2007) and is furthermore induced, amongst other activation pathways, by the MKK7-MAPK cascade 
(Tournier et al. 2001), Tnfα expression levels were determined. Tnfα mRNA was found to be induced in 
the liver 2 hours after treatment. Tnfα expression levels seemed to be higher in MKK7ΔAlfp mice, 
however this difference was not significant. In MKK7Ctrl as well as in MKK7ΔAlfp mice the expression of 
Tnfα was reduced below basal levels 8 hours after treatment (Figure 15). By contrast, on the protein 
level a mild induction of TNFα was seen only in MKK7Ctrl mice 2 hours following LPS/GalN treatment 
(p = 0.057). 8 hours after LPS/GalN challenge TNFα protein levels were similar between MKK7Ctrl and 
MKK7ΔAlfp mice (Figure 16A). The cytokine interleukin-6 (IL-6) also plays an important role in the 
regulation of the acute-phase response to injury and infection by activating, amongst others, MAPK 
cascades (Heinrich et al. 2003). IL-6 protein levels were increased 2 hours after injections and 
decreased 8 hours after LPS/GalN challenge in MKK7Ctrl and in MKK7ΔAlfp mice (Figure 16A). Finally, the 
level of phosphorylated JNK2 (p-JNK2) in liver homogenates was determined 2 hours after induction of 
hepatic damage (Figure 16B). p-JNK2 levels were found to be equal between MKK7Ctrl and MKK7ΔAlfp 
mice and no induction could be detected at this time point. Taken together, the expression and 
induction of Gadd45β and the acute phase cytokines TNFα and IL-6 was found to be similar between 
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MKK7Ctrl and MKK7ΔAlfp mice. Expression of Mkk7, c-Jun, JunB and JunD mRNA was downregulated 2 
hours upon LPS/GalN treatment in MKK7Ctrl animals, whereas LPS/GalN had no apparent effect on the 
expression of these genes in MKK7ΔAlfp liver tissues. 
 
 
  
  
Figure 15: Gene expression analysis of whole livers of LPS/GalN treated and untreated MKK7Ctrl and MKK7ΔAlfp 
mice. Gene expression levels upon LPS/GalN (10µg/kg; 1g/kg) treatments were determined using qPCR. Mice 
were sacrificed after 2 and 8 hours. The baseline (time 0) was set by analysis of PBS-treated mice. PCR reactions 
were done in triplicates. Expression of the β-actin gene was used to normalize the amount of the indicated 
transcripts. PBS MKK7Ctrl n = 4; PBS MKK7ΔAlfp n = 4; LPS 2 hours MKK7Ctrl n = 6; LPS 2 hours MKK7ΔAlfp n = 5; 
LPS 8 hours MKK7Ctrl n = 3; LPS 8 hours MKK7ΔAlfp n = 3; Data are shown as mean values ± SEM. T-test: significant 
differences (p < 0.05) are indicated by asterisks. SEM = standard error of the mean. 
36 
 
xxx 
A 
 
A 
 
 
B 
B 
Figure 16: Determination of TNFα, IL-6 and p-JNK2 protein levels in liver homogenates. [A] TNFα and IL-6 
protein levels in livers of MKK7Ctrl and MKK7ΔAlfp mice was measured by ELISA at the indicated time points after 
LPS/GalN challenge. The baseline (time 0) was set by analysis of PBS-treated mice. Reactions were done in 
triplicates. PBS MKK7Ctrl n = 4; PBS MKK7ΔAlfp n = 4; LPS 2 hours MKK7Ctrl n = 7; LPS 2 hours MKK7ΔAlfp n = 6; 
LPS 8 hours MKK7Ctrl n = 6; LPS 8 hours MKK7ΔAlfp n = 3; Data are shown as mean values ± SEM. T-test: not 
significant [B] Levels of phosphorylated JNK2 in liver lysates 2 hours after LPS/GalN (10µg/kg; 1g/kg) and PBS 
treatment. Reactions were done in triplicates. PBS MKK7Ctrl n = 2; PBS MKK7ΔAlfp n = 2; 
LPS 2 hours MKK7Ctrl n = 7; LPS 2 hours MKK7ΔAlfp n = 6; LPS 8 hours MKK7Ctrl n = 6; LPS 8 hours MKK7ΔAlfp n = 3; 
Data are shown as mean values ± SEM. T-test: not significant. SEM = standard error of the mean. 
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2.2.4 Deletion of MKK7 in the hematopoietic system and the liver 
  
Next, the role of hematopoietic cells in the LPS/GalN liver injury model was examined by using 
Mx1-Cre MKK7Δ/Δ animals (termed MKK7ΔMx1 hereafter). The same dose as for the Alfp-Cre mice was 
used (10 µg/kg LPS, 1 g/kg GalN). The survival curves of MKK7ΔMx1 and MKK7Ctrl mice upon LPS/GalN 
injection are shown in Figure 17A. The observed tendency for a protective function of MKK7 deficiency 
against LPS/GalN induced liver damage is not yet significant (p = 0.06). Furthermore, serum 
transaminase activity (ALT and AST) was not found to be different between MKK7Ctrl and MKK7ΔMx1 
mice when samples were analyzed 8 hours after LPS/GalN challenge (Figure 17B). 
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Figure 17: Survival curves and ALT/AST levels upon LPS/GalN treatment in MKK7ΔMx1 mice. [A] Survival curves 
of MKK7ΔMx1 and MKK7Ctrl mice upon LPS/GalN (10µg/kg; 1g/kg) injection. MKK7Ctrl n = 6; MKK7ΔMx1 n = 5. [B] 
ALT and AST levels of PBS treated MKK7ΔMx1 and MKK7Ctrl mice compared to LPS/GalN treated MKK7ΔMx1 and 
MKK7Ctrl mice. PBS MKK7Ctrl n = 3; PBS MKK7ΔMx1 n = 2; LPS MKK7Ctrl n = 5; LPS MKK7ΔMx1 n = 4; Data are shown 
as mean values ± SEM. T-test: not significant. Samples were taken 8 hours after injections. U/l = units per liter. 
SEM = standard error of the mean. 
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Moreover, no obvious difference in the extent of injury was seen in H&E stained liver sections of 
LPS/GalN challenged control and MKK7ΔMx1 mice (Figure 18). Due to strong background fluorescence of 
red blood cells, apoptosis could not be assayed by TUNEL staining. Hence, an ELISA, detecting 
cytoplasmic histone-associated DNA fragments (mono- and oligonucleosomes) which are a hallmark of 
apoptotic cell death (Bortner et al. 1995), was performed (Figure 19). No significant difference in the 
extent of apoptosis between MKK7Ctrl and MKK7ΔMx1 livers could be determined. Taken together, no 
significant differences between MKK7Ctrl and MKK7ΔMx1 mice were observed when analyzing survival 
times, serum transaminase levels and liver histology. 
 
 
Figure 18: H&E stained liver sections. Liver sections of MKK7Ctrl and MKK7ΔMx1 mice, treated either with PBS or 
LPS/GalN (10µg/kg; 1g/kg) were prepared and stained with H&E. Massively injured livers were seen for both 
genotypes, without any obvious disparities (see inserts). Samples were taken 8 hours after injections. 
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Figure 19: Determination of apoptotic liver damage: Mono- and oligonucleosomes, which are a typical sign 
for apoptosis, were detected in lysates of MKK7Ctrl and MKK7ΔMx1 livers. Reactions were done in triplicates. PBS 
n = 1; LPS n = 5. Data are shown as mean values ± SEM. All samples were taken 8 hours after PBS respectively 
LPS/GalN (10µg/kg; 1g/kg) injections. SEM = standard error of the mean. 
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Figure 20: Gene expression analysis of livers of MKK7Ctrl and MKK7ΔMx1 animals. Gene expression in livers of 
PBS treated and LPS/GalN (10µg/kg; 1g/kg) treated MKK7Ctrl and MKK7ΔMx1 mice was examined by qPCR. PCR 
reactions were done in triplicates. Expression of the β-actin gene was used to normalize the amount of the 
indicated transcripts. PBS MKK7Ctrl n = 4; PBS MKK7ΔMx1 n = 2; LPS MKK7Ctrl n = 6; LPS MKK7ΔMx1 n = 5; Data are 
shown as mean values ± SEM. T-test: significant differences (p < 0.05) between the genotypes are indicated by 
asterisks. Samples were taken 8 hours after injections. SEM = standard error of the mean. 
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2.2.5 Loss of MKK7 in MKK7ΔMx1 livers affects c-Jun protein expression 
 
Next, gene expression analysis of the liver samples was performed 8 hours after LPS/GalN treatment 
(Figure 20). In MKK7Ctrl mice Mkk7 was down-regulated and Gadd45β was induced following hepatic 
injury. The residual Mkk7 expression in MKK7ΔMx1 samples is very likely due to a contamination with 
genomic DNA. As well as in control mice, Gadd45β was strongly induced in MKK7ΔMx1. The basal level 
of c-Jun mRNA was reduced in MKK7ΔMx1 liver tissues compared to MKK7Ctrl mice (p = 0.0009), whereas 
the induction seemed to be unaffected. JunB induction was also found to be similar between MKK7Ctrl 
and MKK7ΔMx1 mice whereas JunD mRNA expression levels remained constant upon LPS/GalN 
treatment for both genotypes. Next, c-Jun levels were analyzed on the protein level (Figure 21A). In 
liver homogenates of PBS treated mice a single band of about 43 kDa was detected. In MKK7Ctrl mice 
that developed liver inflammation a second, elevated band appeared, which indicates an altered 
phosphorylation state (Wang et al. 2010). In LPS/GalN treated MKK7ΔMx1 mice this second band was 
absent, indicating that c-Jun was not phosphorylated (Figure 21A). 
Interestingly, no Tnfα mRNA induction could be detected in MKK7ΔMx1 tissues at the examined time 
point, whereas the amount of Tnfα transcript was significantly increased in inflamed MKK7Ctrl livers 
(p = 0.039). The expression of Tgfβ, which is an important fibrosis marker (Schuppan et al. 1999), was 
unaffected upon LPS/GalN treatment (Figure 20). Next, TNFα, IL-6 and phospho-JNK2 protein levels 
were examined (Figure 21B and 21C). For TNFα as well as for IL-6 a reduction was detected 8 hours 
after LPS/GalN treatment as expected. The level of phospho-JNK2 was reduced in LPS/GalN treated 
MKK7ΔMx1 animals compared to MKK7Ctrl animals. Thus, loss of MKK7 has no apparent effect on late 
transcriptional induction of the c-Jun gene but the loss of MKK7 affects either c-Jun mRNA stability, 
translation, c-Jun protein stability or posttranslational modifications of c-Jun protein. 
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A 
 
B 
 
C 
 
Figure 21: Determination of protein levels in liver homogenates. [A] Western blotting of total c-Jun was 
performed on liver lysates of MKK7Ctrl and MKK7ΔMx1 mice that received PBS injections or were challenged with 
LPS/GalN 8 hours earlier. [B] Homogenates of livers were analyzed for their relative levels of TNFα and IL-6 by 
ELISA. [C] Phospho-JNK2 protein in liver lysates. Reactions were done in triplicates. PBS MKK7Ctrl n = 4; 
PBS MKK7ΔMx1 n = 2; LPS MKK7Ctrl n = 6; LPS MKK7ΔMx1 n = 5; Data are shown as mean values ± SEM. 
T-test: significant differences (p < 0.05) are indicated by asterisks. Samples were taken 8 hours after PBS 
respectively LPS/GalN (10µg/kg; 1g/kg) injections. SEM = standard error of the mean. 
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2.3 Discussion 
 
Over the last years and decades, multiple studies on the role of the TNFα-MKK7-JNK pathway in 
various hepatitis models have been performed. TNFα is a pleiotropic cytokine as is can affect cell 
proliferation as well as programmed cell death (Bradham et al. 1998). The signaling cascades around 
JNK and NF-κB were of special interest as both are induced by TNFα (Song et al. 1997). TNFα induced 
TNFR triggering leads to the activation of NF-κB transcription factors, ultimately promoting cell 
survival (Papa et al. 2004). The outcome of JNK activation depends on the magnitude and duration of 
JNK activity. Whereas transient activation of the JNK cascade signals cell growth and differentiation, a 
sustained activation triggers cell death (Ventura et al. 2006). The pro-survival function of NF-κB 
involves a suppression of the sustained JNK activation (Tang et al. 2001). Thus, the biological outcome 
of TNFα stimulation is dictated, in part, by the balance between the opposing activities of NF-κB and 
JNK (Papa et al. 2008; Wullaert et al. 2007). 
 
Contradictory results were published from single Jnk1 or Jnk2 knockout mice. Whereas Maeda et al. 
reported a considerably reduced ConA-induced liver damage in Jnk1-/- as well as in Jnk2-/- single 
knockout mice (Maeda et al. 2003), Ni et al. observed a protective effect only for liver injury caused by 
ConA/GalN but not by ConA alone (Ni et al. 2008). In either Jnk1 or Jnk2 deficient mice, cytochrome c 
release as well as caspase activation were reduced upon ConA/GalN treatment compared to wild type 
mice, leading to less severe hepatic damage and reduced mortality (Ni et al. 2008). In 2009 Das et al. 
published that no difference was observed in whole-body single knockouts of either Jnk1 or Jnk2 in 
the ConA model, whereas a partial protection was found to be associated with the Jnk1 or Jnk2 
deficiency in the LPS/GalN model, suggesting that JNK1 and JNK2 play redundant roles during the 
pathogenesis of hepatitis.  Mx1-Cre Jnk1fl/fl Jnk2-/- mice exhibited a strong protection against ConA 
induced hepatitis (Das et al. 2009). The same effect was seen in the LPS/GalN model. This protection 
against hepatitis was found to be associated with reduced mortality, reduced serum transaminase 
activity as well as decreased expression of AP-1 related genes and Tnfα mRNA in the liver and 
decreased amounts of serum TNFα. The key conclusions were that JNK is not required for TNFα 
mediated death of hepatocytes but JNK is essential for the expression of TNFα by hematopoietic cells 
that promote hepatitis (Das et al. 2009). The differences between the various hepatitis models might 
explain these discrepancies. For example, the key regulator TNFα is produced by different cell 
populations in the LPS and ConA model and ConA induces only necrosis whereas LPS/GalN leads to 
necrosis and apoptosis (Ni et al. 2008). Furthermore the knockout strategy has to be considered, as 
there were whole-body knockouts as well as tissue and cell type specific knockouts. Thus, variations in 
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experimental setups may contribute to the inconsistent results concerning the JNK pathway in the 
context of acute hepatitis. 
To shed more light on this pathway, the relevance of the upstream activator of JNK, MKK7, in acute 
hepatitis was examined. Previously it has been shown that disruption of MKK7 is sufficient to prevent 
JNK activation caused by proinflammatory cytokines such as TNFα (Tournier et al. 2001). Therefore 
Mkk7fl/fl mice were crossed to either Alfp-Cre transgenic mice or Mx1-Cre transgenic mice, 
respectively. Previously it has been shown in our lab, that ConA challenge of Mx1-Cre Mkk7fl/fl mice 
resulted in increased serum transaminase levels, whereas no change was observed with 
Alfp-Cre Mkk7fl/fl mice. However, the overall survival and hepatic damage in Mx1-Cre Mkk7fl/fl mice 
was found to be similar to wildtype mice, indicating that MKK7 does not protect against ConA induced 
hepatitis (unpublished data). 
In this study, Alfp-Cre Mkk7fl/fl and Mx1-Cre Mkk7fl/fl mice were subjected to LPS/GalN treatments. On 
the basis of the publication by Das et al. no effect was expected to be seen with the Alfp-Cre Mkk7fl/fl 
(MKK7ΔAlfp) mice, whereas a protective effect of Mx1-Cre mediated deletion of the floxed allele 
(MKK7ΔMx1) was anticipated. Indeed, no prolonged survival or altered serum transaminase levels could 
be detected in MKK7ΔAlfp mice as compared to MKK7Ctrl animals upon LPS/GalN injections. 
Furthermore, quantification of TUNEL stainings revealed an equal extent of apoptotic liver damage in 
knockout and control animals. Thus, hepatocyte specific deletion of MKK7 does not confer protection 
from LPS/GalN induced hepatitis. 
LPS/GalN challenge of MKK7ΔMx1 mice revealed a mean survival time of 8.48 ± 1.28 hours, whereas the 
mean survival time for MKK7Ctrl animals was 7.12 ± 1.28 hours. However, this result is not statistically 
significant as the p-value is 0.06. Interestingly no difference in serum transaminase levels could be 
detected and histological analyses indicated a similar liver damage in control and mutant mice. 
Although additional experiments need to be performed, the survival curves suggest a trend for a 
protective effect of hematopoietic deletion of MKK7. 
Gene expression analyses revealed that the basal expression of c-Jun was reduced in MKK7ΔAlfp and 
MKK7ΔMx1 liver tissues, whereas upon treatment with LPS/GalN normal c-Jun induction occurred. 
Interestingly, no induction of c-Jun protein or c-Jun phosphorylation could be detected by Western 
blot analyses in MKK7ΔMx1 livers. The other examined AP-1 factors, JunB and JunD, displayed the same 
mRNA expression patterns in MKK7Ctrl and MKK7ΔMx1 mice. Two hours after LPS/GalN challenge a 
downregulation of JunD mRNA was observed in MKK7Ctrl livers, while the expression was constant in 
MKK7ΔAlfp livers. TNFα and IL-6 protein levels in the liver were reduced 8 hours upon LPS/GalN 
injections and no differences were observed between knockout and control tissues. These low protein 
levels are consistent with the previously reported kinetics of TNFα and IL-6 expression following LPS 
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challenge. TNFα expression peaks 1 hour after LPS challenge, IL-6 expression after 3 hours and both 
proteins disappear rapidly after reaching maximum expression (Chensue et al. 1991). Therefore TNFα 
as well as IL-6 protein levels have to be assayed at earlier time points. The same reduction after 8 
hours was seen for phospho-JNK2.  
 
Other studies focused on the JNK pathway in the context of liver regeneration. To understand the 
crosstalk between NF-κB and JNK, the authors examined a putative mediator of this crosstalk, 
Gadd45β, in the context of partial hepatectomy (PH) (Papa et al. 2008). In contrast to ConA or LPS 
challenge, PH normally induces a transient, but not prolonged, JNK activation via TNFR signaling 
(Kamata et al. 2005), which is required for hepatocyte proliferation (Schwabe et al. 2003). Gadd45β is 
known to be rapidly induced by PH (Su et al. 2002) and, moreover, is known to directly interact with 
the upstream activator of JNK, MKK7, thereby blocking its catalytic activity (Papa et al. 2004). 
Gadd45β-/- mice were found to exhibit impaired hepatocyte proliferation and increased cell death 
following PH. Interestingly, Gadd45β ablation did not affect hepatotoxic JNK signaling after ConA or 
LPS challenge, although both treatments are known to induce Gadd45β expression (Papa et al. 2008). 
Consistent with this study, Gadd45β upregulation upon LPS/GalN challenge was detected in our 
experiments. No significant difference in the expression level of Gadd45β was detected between 
control and mutant mice. This specific role of Gadd45β mediated JNK suppression during liver 
regeneration may be explained by the differences between transient (PH) and sustained (ConA, LPS) 
JNK activation. One difference is the involvement of reactive oxygen species (ROS). Whereas ROS are 
elevated following prolonged JNK activation, this elevation is not involved in the transient induction of 
JNK elicited by PH (Kamata et al. 2005; Papa et al. 2008).  
Furthermore, TNF-R1 and c-Jun deficiency were shown to be associated with defective liver 
regeneration following PH (Yamada et al. 1997; Behrens et al. 2002) and Mkk7 deficient mouse 
embryonic hepatoblasts were found to display impaired proliferation (Wada et al. 2008). These 
findings suggest that MKK7 might be involved in liver regeneration. To further examine the functions 
of MKK7 in liver regeneration, PH experiments using MKK7ΔAlfp as well MKK7ΔMx1 mice should be 
performed in the future. 
 
Taken together, no definite role for MKK7 in hepatitis was found. Nevertheless, our results partly 
reflect the data from Jnk1/Jnk2 double mutants, however, the observed phenotype is very mild and 
more experiments are needed to further explore this pathway in hepatitis. 
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3 Materials and Methods 
 
3.1 Project „New Tools for Mouse Genome Engineering“ 
3.1.1 ES cell culture 
 
Mouse embryonic stem cells (ESCs) were cultured on feeder cells on gelatinzed cell culture dishes at 
standard conditions (37°C, 5 % CO2). As feeder cells, mouse embryonic fibroblasts that have been 
arrested mitotically by treatment with mitomycin C were used. All culture media were filter sterilized 
(0.45 µm) before usage. Culture medium for ESCs was exchanged every day. When the desired density 
was reached, cells were washed with PBS twice and then incubated with trypsin (0.05 %) for 5 minutes 
at 37°C to detach from the surface of the cell culture dish. The enzymatic activity of trypsin was 
stopped by resuspending the cells in culture medium. Cells were pelleted at 1150 rpm for 5 minutes, 
resuspended in culture medium and then plated at the desired density. Alternatively cells were 
resuspended in 1 ml of freezing medium and frozen at -80°C or in liquid nitrogen.  
 
ESC culture medium Fibroblast culture medium 
DMEM DMEM 
10 % ESC tested FCS 10 % FCS 
1x Penicillin/Streptomycin 1x Penicillin/Streptomycin 
2 mM L-Glutamin 2 mM L-Glutamin 
1 mM Sodium pyruvate  
1x Non-essential amino acids  
50 nM beta-Mercaptoethanol  
103 U/ml LIF  
  
Freezing medium Gelatine 
90 % FCS 0.1 % Gelatine 
10 % DMSO PBS 
 
3.1.2 Characterization of stem cells 
3.1.2.1 Alkaline phosphatase staining 
 
After washing cells 2 times with PBS, AP substrate solution (Vector Shields) was prepared according to 
the protocol and cells were incubated with for 20-30 minutes at 37°C in the dark. The staining solution 
was then removed, cells were washed with PBS and analyzed using a brightfield microscope. 
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3.1.2.2 DNA preparation 
 
To derive DNA from cultured cells, plates were washed with PBS twice, covered with ESC lysis buffer 
and incubated at 37°C overnight. The next day the contents of the wells were transferred to 2 ml 
microcentrifuge tubes and filled to 500 µl with ESC lysis buffer. Upon adding 200 µl NaCl (5 M) tubes 
were shaken vigorously and centrifuged at 13.000 rpm for 10 minutes. Supernatants were transferred 
to fresh tubes, 500 µl isopropanol was added and tubes were inverted several times to precipitate the 
DNA. The samples were centrifuged at 13.000 rpm for 5 minutes, supernatants discarded and the DNA 
pellets washed with 70 % ethanol. After another centrifugation and removal of the ethanol, pellets 
were air dried and dissolved at 65°C for 30 minutes in 50 to 100 µl TE buffer. 
 
ESC lysis buffer TE buffer 
1 mM Tris/HCl pH 8.0 10 mM Tris/HCl pH 8.0 
5 mM EDTA 1 mM EDTA 
100 mM NaCl  
1 % SDS  
0.5 mg/ml Proteinase K  
 
3.1.2.3 RNA preparation 
 
To reduce the number of feeder cells in the sample, cells were trypsinized and transferred to a new 
cell culture dish. After about half an hour, most feeder cells have attached to the surface, whereas 
most of the stem cells are still floating. The cell suspension was then centrifuged, the supernatant 
removed and the pellet either processed immediately or frozen at -20°C. For RNA extraction, the 
RNeasy Mini Kit (Qiagen) was used. RNA concentrations were measured by use of the NanoDrop 1000 
Spectrophotometer (Peqlab). 
 
3.1.2.4 cDNA synthesis  
 
For synthesis of first-strand cDNA templates from the purified RNA, Ready-To-Go™ You-Prime First-
Strand Beads (GE Healthcare) were used. 2 µg total RNA were transcribed using Oligo(dT)18 primer 
(Fermentas) at the recommended concentration. 
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3.1.2.5 Quantitative real-time PCR (qPCR) of stem cell specific genes 
 
qPCRs were performed on MyiQ and iQ5 Real Time PCR Detection Systems (Bio-Rad) using the 
iQ™SYBR® Green Supermix (Bio-Rad). Reaction set up, used primers and program are indicated below. 
Analysis was done in Microsoft Excel® by the delta-CT method.  Results were normalized to β-actin 
expression. cDNA transcribed from RNA, which was extracted from feeder cells, was used as a 
negative control for stemness markers.  
 
qPCR mix 
12.5 µl iQ mix 
2 µl primer mix (forward + reverse, 10 µM each) 
0.5 µl nuclease-free water 
10 µl cDNA (1:40 dilution) 
 
Program: 
50°C 10 min 
    95°C 5 min 
    95°C 10 sec 
 45 cycles   58°C 30 sec real time 
detection   65°C 30 sec 
  95°C 1 min 
    65°C 10 sec melting curve: 61 cycles; + 0.5°C per cycle 
15°C ∞ 
     
Name Sequence 
Nanog_fwd AGGGTCTGCTACTGAGATGCTCTG 
Nanog_rev CAACCACTGGTTTTTCTGCCACCG 
Oct3/4_fwd TCTTTCCACCAGGCCCCCGGCTC 
Oct3/4_rev TGCGGGCGGACATGGGGAGATCC 
Sox2_fwd TAGAGCTAGACTCCGGGCGATGA 
Sox2_rev TTGCCTTAAACAAGACCACGAAA 
Utf1_fwd GGATGTCCCGGTGACTACGTCTG 
Utf1_rev GGCGGATCTGGTTATCGAAGGGT 
Gdf3_fwd GTTCCAACCTGTGCCTCGCGTCTT 
Gdf3_rev AGCGAGGCATGGAGAGAGCGGAGCAG 
Cripto_fwd ATGGACGCAACTGTGAACATGATGTTCGCA 
Cripto_rev CTTTGAGGTCCTGGTCCATCACGTGACCAT 
Ecat1_fwd TGTGGGGCCCTGAAAGGCGAGCTGAGAT 
Ecat1_rev ATGGGCCGCCATACGACGACGCTCAACT 
Ulk1_fwd GGAGACCTGGCTGACTACCTGCA 
Ulk1_rev CCTGACAGTGTCTTCACTCAGTGT 
Eras_fwd ACTGCCCCTCATCAGACTGCTACT 
Eras_rev CACTGCCTTGTACTCGGGTAGCTG 
Rex1_fwd ACGAGTGGCAGTTTCTTCTTGGGA 
Rex1_rev TATGACTCACTTCCAGGGGGCACT 
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Nat1_fwd ATTCTTCGTTGTCAAGCCGCCAAAGTGGAG 
Nat1_rev AGTTGTTTGCTGCGGAGTTGTCATCTCGTC 
Cdx2_fwd GGCGAAACCTGTGCGAGTGGATGCGGAA 
Cdx2_rev GATTGCTGTGCCGCCGCCGCTTCAGACC 
Fgf4_fwd CGTGGTGAGCATCTTCGGAGTGG 
Fgf4_rev CCTTCTTGGTCCGCCCGTTCTTA 
 
3.1.2.6 Generation and analysis of embryoid bodies 
 
For generation of embryoid bodies (EBs), ESCs were trypsinized for 5 minutes and 50 to 200 µl of the 
cell suspension were transferred onto bracterial grade culture dishes with ESC medium without LIF.  
Medium was exchanged every day. After 7 days in culture, the EBs were spun down, RNA was 
prepared and cDNA was synthesized as described in sections 3.1.2.3 and 3.1.2.4. qPCRs using the 
primers listed below were performed in order to confirm the presence of cells of all 3 germ layers 
within the EBs. For reaction set up and temperature protocol see section 3.1.2.5. 
 
Name Sequence 
Cdx2_fwd GGCGAAACCTGTGCGAGTGGATGCGGAA 
Cdx2_rev GATTGCTGTGCCGCCGCCGCTTCAGACC 
Brachyury_fwd CATGTACTCTTTCTTGCTGG 
Brachyury_rev GGTCTCGGGAAAGCAGTGGC 
Gss_fwd GCGAGCAGCTGGCCAGGAAGGTGCAC 
Gss_rev CAGCTAGCTCCTCGTTGCTTTCTC 
Sox2_fwd GAAGGGGAGAGATTTTCAAAGAGATACAAG 
Sox2_rev CCAGATCTATACATGGTCCGATTCCC 
Afp2_fwd CCTATGCCCCTCCCCCATTC 
Afp2_rev CTCACACCAAAGCGTCAACACATT 
Hnf_fwd TGCCCTCTCACCTCAGCAATG 
Hnf_rev CCCCTCAGCACACGGTTTTG 
Foxa2_fwd GTATGCTGGGAGCCGTGAAG 
Foxa2_rev CAGCGCCCACATAGGATGAC  
Vimentin_fwd GCACTAACGAGTCCCTGGA 
Vimentin_rev GTGGGTGTCAACCAGAGGA 
 
3.1.3 Analysis of transgenic mice 
 
Genomic DNA for genotyping was obtained by incubating tail or ear biopsies overnight at 55°C with 16 
µl of tail buffer plus 4 µl proteinase K. To inactivate the enzymatic activity of proteinase K, the lysate 
was heated at 99°C for 10 minutes the next day.  After diluting the DNA with 180 µl water the sample 
was used directly for PCR reactions without further purification. The presence of the transgene was 
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proven by PCR detecting PyMT and Cre sequences. All buffers used, primer pairs and programs are 
listed below. 
  
Tail buffer  10X PCR buffer  PCR mix 
100 mM Tris/HCl pH 8.5  200 mM Tris pH 8.9  36 µl H2O 
5 mM EDTA  300 mM KCl  5 µl 10X PCR buffer 
200 mM NaCl  100 mM (NH4)2SO4  4 µl dNTPs (2.5 mM) 
0.1 % SDS  15 mM MgCl2  1 µl primer 1 (10 µM) 
    1 µl primer 2 (10 µM) 
    1 µl Taq polymerase 
    2 µl template DNA 
 
Programs: 
PyMT 
 
Cre 
 95°C 1.5 min 95°C 1.5 min 
 95°C 30 sec 
40 cycles 
95°C 10 sec 
35 cycles 58°C 30 sec 55°C 10 sec 
72°C 1 min 72°C 25 sec 
72°C 5 min 
 
4°C ∞ 
 4°C ∞ 
     
Name Sequence 
PymTsense GGAAGCAAGTACTTCACAAGG 
PymTantisense GGAAAGTCACTAGGAGCAGGG 
Cre1 CTGCCACGACCAAGTGACAGCAATG 
Cre2 GCCTTCTCTACACCTGCGGTGCTAA 
 
In order to detect PyMT mRNA expression, female mice were sacrificed and dissected. Organs were 
harvested and snapfrozen on dry ice. RNA was prepared and transcribed into cDNA as described in 
sections 3.1.2.3 and 3.1.2.4. PyMT PCR was performed as described above using the generated cDNA 
as templates. 
 
3.1.4 The exchange vector system 
3.1.4.1 Molecular cloning 
 
Generation of the docking vector (DV): A modified hygromycin resistance gene was cut out of the 
plasmid pBA14 by the enzymes BglII and NheI and inserted into the corresponding sites of plasmid 
pCcall2IE. The newly derived construct was ligated via AscI and AsiSI and cloned into the vector 
pROSA-modified to obtain the docking vector plasmid. 
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Generation of the exchange vector (EV): A βGEO-STOP-loxP cassette was amplified from the plasmid 
pCcall-modified via PCR by use of the primers “NheIΔ5’βgeo_FWD” and “Δ5’βgeo_REV”, thereby 
adding BglII and NheI overhangs. The PCR reaction was run on a 1 % agarose gel and the PCR product 
was purified by use of the QIAquick Gel Extraction Kit (Qiagen). The purified DNA was then cloned into 
a commercial (TOPO® TA Cloning® Kit (with pCR®2.1-TOPO®) with One Shot TOP10 Chemically 
Competent E. coli, Invitrogen) vector. The plasmid TOPO- βGEO was verified by DNA sequence 
analysis. A small linker oligonucleotide (called TV1) was inserted into the KpnI and BglII sites of a 
modified version of pBlue. pBlue-TV1 and TOPO-βGEO were both cut with BglII and NheI and then 
ligated. After digesting the resulting plasmid with BglII and SacII, a second linker oligonucleotide (TV2) 
was incorporated. The cloning steps are outlined in Figure 22. 
 
 
Figure 22: Generation of the docking vector. Schematic drawing of the plasmids used to generate the docking 
vector construct. HYG, hygromycin resistance gene; HYG-mut, mutated hygromycin resistance gene; CAG 
coding sequence for the cytomegalovirus promoter fused with the chicken β-actin promoter; IRES-EGFP, 
internal ribosome entry site followed by the coding sequence for enhanced green fluorescent protein; pA, 
polyadenylation signal; attP sites, direct the recombination mediated by ΦC31 integrase; AscI, AsiSI, BglII, NheI, 
restrictions enzymes; 
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Bacterial culture 
DNA fragments were ligated with a T4 DNA ligase (Roche) overnight at 16°C. Reactions were set up in 
a total volume of 10 to 30 µl. The amounts of vector and insert were chosen by setting them in a 
molar ratio of 1:3, 1:5 or 1:7. The next day the ligated plasmid was transformed into chemically 
competent E.coli (Turbo). In brief, competent bacteria were thawed on ice, 2 µl of ligation reaction 
were added and contents were mixed gently by flicking the tube. After incubating on ice for up to 30 
minutes, a heatshock was done (45 seconds, 42°C). Bacteria were chilled on ice, 250 µl of LB medium 
was added and bacteria were incubated at 37°C for 1 hour on a shaker. Then the bacterial suspension 
was plated on LB agar plates with ampicillin and incubated overnight at 37°C. Next, single colonies 
were picked and inoculated in 2 ml LB medium containing 50 µg/ml ampicillin. Following another 
overnight incubation (37°C, under agitation) plasmid DNA was extracted by use of the QIAprep Spin 
Miniprep Kit (Qiagen). The derived samples were analyzed by PCR or restriction digests to proof the 
successful ligation. 50 to 500 ml of LB medium were inoculated with positive cultures, incubated 
overnight and plasmid DNA was prepared by use of QIAGEN Plasmid Midi or Maxi Kits. 
 
Linker Hybridisation 
To insert a small DNA fragment into a plasmid, the sense and the antisense oligonucleotide were 
mixed 1:1 and then diluted with water 1:200. The reaction was heated to 95°C for 5 minutes on a 
heating block. The block was then switched off and the tube was kept on the block until it reached 
room temperature. Following that, the linker was put on ice until further use. The linker and the 
plasmid were then ligated as described above. 
 
Name Sequence 
NheIΔ5’βgeo_fwd TTGCTAGCGCGGATCCCGTCGTTTTACA 
Δ5’βgeo_rev TTCTCGAGCGGGTACCCAAGATCTATAACTT 
Linker 
TV1 sense CCGGGTGCCAGGGCGTGCCCTTGGGCTCCCCGGGCGCGTAGCTAGCA 
Linker 
TV1 antisense GATCTGCTAGCTACGCGCCCGGGGAGCCCAAGGGCACGCCCTGGCACCCGGGTAC 
Linker 
TV2 sense 
GATCTTCTAGACTCGAGCGGGTGCCAGGGCGTGCCCTTGGGCTCCCCGGGCGCGTAC
CGC 
Linker 
TV2 antisense GGTACGCGCCCGGGGAGCCCAAGGGCACGCCCTGGCACCCGCTCGAGTCTAGAA 
 
3.1.4.2 Preparation of plasmids for electroporation 
 
100 µg docking vector DNA were digested with 10 µl PacI restriction enzyme (New England Biolabs) 
overnight at 37°C. Next, the plasmid DNA was purified by phenol-chloroform (P/C) precipitation. 1 
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volume of P/C was added to the DNA and the tube shaken vigorously. To separate the aqueous phase 
from the organic phase the mixture was centrifuged at 13.000 rpm for 5 minutes. The upper phase 
was transferred to a fresh microcentrifuge tube and 1/10 volume of sodium acetate (3M, pH 5.2) and 
2 volumes of ethanol (100 %) were added, followed by another centrifugation. The supernatant was 
removed and the DNA pellet washed with ethanol (70 %) two times. After about 20 minutes air drying 
50 µl of PBS were added and the pellet was dissolved at 37°C for 1 hour.  
 
3.1.4.3 Electroporation of A9 ESCs with docking vector 
 
For targeting A9 cells with the docking vector (DV) construct, 1 x 107 cells were resuspended in 1 ml 
medium and transferred to an electroporation cuvette (Gene Pulser® Cuvette, 0.4 cm electrode gap; 
Bio-Rad) together with 30 µg of purified DV DNA. The cuvette was inserted into the GenePulser XCell 
(Bio-Rad) and electroporation was performed by one single pulse (260 V, 500 µF). Cells were then kept 
on ice for 10 minutes to recover and plated on 9 cell culture plates (Ø 10 cm) with hygromycin-
resistant feeder cells and ESC medium. As a negative control about 1 x 106 cells in 1 ml medium 
without vector DNA were treated in the same way and seeded on 1 plate. Selection for hygromycin 
resistant clones was started the next day by supplying the cells with medium containing 100 µg/ml 
hygromycin. Selection medium was changed every day. After 2 to 3 days cell death could be observed. 
Selection was continued until no living cells were left on the negative control plate and colonies of 
resistant cells with round shape and distinct borders had formed on the other plates. Nine days after 
electroporation resistant clones were picked with a 20 µl pipette under a stereomicroscope. Picked 
clones were first kept in PBS in 96-well plates with round bottoms (U96 MicroWell™ Plates, Nunc), 
then treated with trypsin and brought to single-cell suspension by pipetting. Upon stopping the trypsin 
reaction by adding ESC medium, cells were transferred to 96-well cell culture dishes with feeder cells 
under continuous hygromycin treatment. When the desired density was reached, cells were split to 2 
new 96-well plates with feeders and 2 96-well plates with gelatin only. As soon as the cells grown on 
feeders were dense enough, they were washed, trypsinized and 120 µl of 96-well freezing medium 
were added to each well followed by vigorous pipetting. Plates were wrapped with Parafilm, paper 
towels and aluminum foil, and frozen at -80°C. Cells grown on gelatin only were expanded to 24-wells 
for DNA preparation for Southern blot analysis. Here cells were cultured until confluent, lysed and 
DNA was extracted as described in section 3.1.2.2. 
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96-well freezing medium (1 well) 
15 µl DMSO 
25 µl ESC medium without antibiotics 
80 µl FCS 
 
3.1.4.4 Southern blot analysis 
 
30 µl of each prepared DNA sample was digested with 5 µl BamHI (Roche) overnight at 37°C. The next 
day samples were run on a 0.7 % agarose gel with TAE buffer. Following electrophoresis the gel was 
first shaken gently in denaturation buffer for half an hour at room temperature and then in 
neutralization buffer for 20 minutes. The membrane (Porablot Membrane NY Plus, Macherey-Nagel) 
was soaked in water before assembly. Then the blotting stack was built as shown in Figure 23. The 
next day the stack was disassembled and the membrane was shaken in 4x SSC buffer for 20 minutes 
before it was air dried and UV cross-linked. The membrane was prehybridized with hybridization 
buffer (PerfectHyb Plus Hybridization Buffer, Sigma) for 1 hour at 65°C. Meanwhile the probe, 
complementary to the 5’ arm of the ROSA26 locus (donation of C. Hartmann), was prepared. 20 to 50 
ng of the probe were brought to a volume of 50 µl with TE buffer and denatured at 99°C for 5 minutes. 
Upon chilling on ice the probe was labeled with 5 µl dCTP-32P using Ready-to-Go DNA Labeling Beads 
(GE Healthcare) according to the protocol. The probe was then purified (illustra ProbeQuant™ G-50 
Micro Columns, GE Healthcare), boiled at 99°C for 3 minutes and added to the membrane. 
Hybridization was done overnight at 65°C. The next day the membrane was washed with wash buffer 
two times for half an hour and the radioactive signal was detected using a phosphoimager screen.  
 
TAE buffer Denaturing buffer Neutralisation buffer 
40 mM Tris acetate 0.5 M NaOH 0.05 M NaPi pH 7.2 
5 mM Sodium acetate 1.5 M NaCl  
1 mM EDTA   
   
SSC buffer Washing buffer  
150 mM NaCl 0.02 M NaPi pH 7.2  
15 mM Sodium citrate 1 % SDS  
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Figure 23: Southern Blotting stack. Schematic drawing of the construction of the blotting stack. 
 
3.1.4.5 Electroporation of targeted A9 cells with exchange vector 
 
Frozen plates were thawed quickly at 37°C and the respective clones were expanded. The clones were 
expanded to a cell number of 1 x 107 and the exchange vector together with a plasmid coding for the 
ΦC31 integrase (EV : integrase = 1:3) was delivered to the cells by electroporation. Cells were then 
plated on G418-resistant feeder cells and selection with G418 (300 µg/ml) was started the next day. 
Neo-resistant clones were expanded and frozen. 
 
3.1.4.6 Proof of successful exchange by PCR 
 
Clones were tested for the presence of the hygromycin or neomycin resistance genes in their genomes 
by performing PCR. The PCR reaction mastermix was described in section 3.1.3, primer sequences and 
the temperature protocols are indicated below. 
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Programs: 
Neo 
 
Hygro 
 95°C 1.5 min 95°C 1.5 min 
95°C 30 sec 
35 cycles 
95°C 30 sec 
35 cycles 52°C 30 sec 58°C 30 sec 
72°C 1 min 72°C 1 min 
72°C 5 min 
 
72°C 5 min 
 4°C ∞ 
 
4°C ∞ 
  
Name Sequence 
Neo_fwd GTGGAGAGGCTATTCGGCTATGACT 
Neo_rev CTTGAGCCTGGCGAACAGTTCGGCT 
Hyg_fwd GGGCGAGATCTGCGGATCTCAAAAAGC 
Hyg_rev TGGGGCGCTAGCCTATTCCTTTGCCCTCG 
 
3.1.4.7 LacZ staining 
 
To show the activity of the enzyme β-galactosidase, lacZ staining was performed. Cells that express β-
galactosidase will turn blue when the substrate “Bluo-Gal” is added. Medium was removed and plates 
were washed with PBS twice. Cells were fixed with 4 % PFA for 10 minutes at RT and then washed 
again with PBS. Cells were then covered with staining solution, and plates were wrapped with Parafilm 
and incubated at 37°C without CO2 overnight. The next day, the staining solution was removed, plates 
were washed and analyzed. 
 
500 mM K3 Stock LacZ Staining Solution 
3.28 g K3 (Fe(III)(CN)6) 10 ml PBS 
20 ml H2O 2 ml K3 stock 
 2 ml K4 stock 
500 mM K4 Stock 0.5 ml Sodium deoxycholate stock solution (1 %) 
4.24 g K4 (Fe(II)(CN)6) 0.1 ml MgCl2 (1 M) 
20 ml H2O 10 µl NP-40 
 1.25 ml Bluo-Gal stock 
40 mg/ml Bluo-Gal Stock fill with PBS to 50 ml 
100 mg Bluo-Gal  
2.5 ml Dimethylformamide  
 
3.1.4.8 Infection of DV-EV cells with AdenoCre 
 
In order to remove the cassette between the loxP sites in the double-targeted cells (DV-EV), cells were 
infected with an adenovirus carrying a Cre transgene (Ad5CMVCre-eGFP, University of Iowa Gene 
Transfer Vector Core, 3 x 1010 PFU/ml). Different amounts (1 µl, 0.5 µl, 0.25 µl, 0.1 µl) of virus were 
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added to 4 x 104 cells in 100 µl ESC medium in a microcentrifuge tube followed by incubation at 37°C 
and 5 % CO2 for six hours. Infected cells were washed twice with PBS and plated on 2 6-wells with 
feeder cells. The following days plates were analyzed for EGFP expression under a fluorescence 
microscope (488 nm).   
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3.2 Project “Evaluation of the Role of MKK7 in Hepatitis“ 
3.2.1 Mice 
 
Alfp-Cre mice (Kellendonk et al. 2000), Mx1-Cre mice (R Kühn et al. 1995) as well as MKK7 fl/fl mice 
(Schramek et al. 2011) have been published previously. All mice were bred and maintained in the 
animal facilty of IMBA according to an ethical animal license protocol complying with the current 
Austrian law. 
 
3.2.2 Genotyping 
 
Preparation of genomic DNA from tail or ear biopsies and the PCR mastermix are described in section 
3.1.3. Primers used and protocols are indicated below. By use of the primers MKK7_wt/fl_fwd and 
MKK7_wt/fl_rev the presence of the wild type or the floxed allele could be detected. This reaction 
could either give a 234 bp band, representing the wild type allele, a 304 bp band, representing the 
floxed allele or, in a heterozygous case, both bands. In Mx-1 Cre mice with at least one floxed allele, a 
delta allele is generated upon induction of the Cre transgene. This was verified by use of the primers 
MKK7-/-fwd and MKK7-/-rev, which amplify a product of 300 bp length. The same primer pair (Cre1 
and Cre2) was used to detect the Mx-1 Cre as well as the Alfp-Cre transgene. All used buffers, primer 
pairs and programs are listed below. 
  
Name Sequence 
MKK7_wt/fl_fwd CTGCCTGTAGCATGCCCGAGCTGTC 
MKK7_wt/fl_rev AGCTGTCTCATCTGTGCACCTCCCAGC 
MKK7-/-fwd  ATGCAGGCCATTGGGAAGTACCAAG 
MKK7-/-rev AGAAAAATGAAGCCCGACTGTGCCT 
Cre1 CTGCCACGACCAAGTGACAGCAATG 
Cre2 GCCTTCTCTACACCTGCGGTGCTAA 
 
Programs: 
MKK7 wt/fl 
 
MKK7 -/- 
 
Cre 
  94°C 1.5 min 94°C 1 min 
 
95°C 1.5 min 
94°C 20 sec 
40 cycles 
94°C 45 sec 
40 cycles 
95°C 10 sec 
35 cycles 68°C 30 sec 63°C 45 sec 55°C 10 sec 
72°C 5 min 
 
72°C 45 sec 72°C 25 sec 
4°C ∞ 
 
72°C 5 min 
 
4°C ∞ 
 
   
4°C ∞ 
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3.2.3 Poly(I:C) injections of Mx-1 Cre mice 
 
To induce the expression of the Cre transgene controlled by the Mx-1 Cre promoter, 6 to 12-week-old 
mice were injected intraperitoneally (i.p.) with poly(I:C) (Invivogen, 13 mg/kg) three times (day 1 – day 
3 – day 5). Further experiments were started 2 weeks later. 
 
3.2.4 LPS/GalN injections 
 
In order to induce hepatic damage, mice received i.p. injections of LPS/GalN (LPS: 10 µg/kg, 
GalN: 1 g/kg). In control-treated animals only the carrier solution (PBS) was administered. Depending 
on the specifications of the experiment, mice were either observed until they died because of the liver 
injury or were sacrificed at defined time points.  
 
3.2.5 Collection of blood and measurement of ALT/AST levels 
 
Wherever possible blood was collected from the portal vein, transferred to EDTA-coated tubes and 
kept on ice until further processing. After centrifugation at 3000 rpm for 15 minutes, serum was 
transferred into fresh tubes and stored at 4°C (short term) or -20°C (long term). 50 µl of serum were 
diluted with 150 µl water and ALT and AST levels were determined by use of the Cobas c 111 analyzer 
(Roche). When necessary, higher dilutions were prepared.  
 
3.2.6 Collection of tissues 
 
Livers were removed and a part of each organ was snap-frozen on dry ice and stored at -80°C for later 
assays. One lobe of the liver of each mouse were put into a fixative (Roti®-Histofix 4 %) and kept at 4°C 
overnight. 
 
3.2.7 Preparation of protein extracts from liver and spleen 
 
Protein extracts were produced using the homogenizer Precellys 24 (Peqlab) together with the 
recommended tubes and ceramic beads. Depending on the further use, tissues were either lysed in 
ProteoJET™ Mammalian Cell Lysis Reagent from Fermentas (ELISA) or in RIPA buffer (Western blot 
analysis) after adding Halt Protease and Phosphatase Inhibitor Cocktail (Pierce). After homogenization, 
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lysates were centrifuged (13000 rpm, 15 minutes, 4°C) and supernatants transferred to fresh 1.5 ml 
tubes. Protein extracts were stored at -80°C. 
 
RIPA buffer 
150 mM NaCl 
50 mM Tris/HCl pH 8.0 
1 % Triton X-100 
0.5 % Sodium deoxycholate 
0.1 % SDS 
 
3.2.8 Measurement of protein concentrations 
 
Protein concentrations were determined by use of the Bradford method. 900 µl of water were 
combined with 200 µl Bradford reagent (Bio-Rad) and 1 ml of that was transferred to a disposable 
cuvette. 2 µl of protein lysate were added and mixed well with the diluted Bradford reagent by 
repeatedly inverting the cuvette. The optical density (OD) at a wave length of 595 nm was measured 
by an Eppendorf BioPhotometer.  
 
3.2.9 Western blot analysis 
3.2.9.1 SDS-PAGE 
 
Proteins contained in the extracts were separated according to their size on a denaturating 
polyacrylamide gel (SDS-PAGE). The components of the separating gel were added to water, mixed, 
filled into disposable cassettes (Invitrogen) and topped with isopropanol. Following polymerization, 
isopropanol was removed, the stacking gel was cast on top of the separating gel and combs with the 
desired pocket size and number were inserted. 
 
Seperating gel – 12 % (1 minigel) Stacking gel – 4 % (1 minigel) 
1.55 ml H2O 1.5375 ml H2O 
2.875 ml Tris/HCl 1.0 M pH 8.8 0.625 ml Tris/HCl 0.5 M pH 6.8 
3.0 ml AA 0.335 ml AA 
37.5 µl SDS 20 % 12.5 µl SDS 20 % 
37.5 µl APS 10 % 12.5 µl APS 10 % 
5.0 µl TEMED 2.5 µl TEMED 
 
20 to 100 µg of protein was used per sample. Protein samples were prepared by diluting the protein 
lysates with water to the desired volume (20 µl for 12-well combs, 50 µl for 10-well combs) and adding 
5X Laemmli buffer containing 3 % β-mercaptoethanol. Prior to use the samples were boiled at 99°C for 
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5 minutes. Gels were placed into the electrophoresis equipment (Invitrogen XCell SureLock™ Mini-
Cell) and the chamber was filled with 1X SDS PAGE Running buffer. Samples were loaded carefully and 
gels were run at 80 volts until the dye front entered the separating gel and then at 120 V until the dye 
front reached the bottom of the gel. PageRuler™ Prestained Protein Ladder (Fermentas) was used as a 
size reference. 
 
5X Laemmli Buffer 1X SDS PAGE running buffer 
0.15 M Tris/HCl pH 6.8 25 mM Tris base 
5 % SDS 190 mM Glycine 
25 % Glycerol 0.1 % SDS 
0.01 % Bromphenol Blue  
 
3.2.9.2 Western blotting 
 
After electrophoresis cassettes were opened and gels placed in transfer buffer. Transfer membranes 
(Millipore Immobilon Transfer Membrane) were cut to the same size as the gel, activated in methanol 
for 5 minutes and put into transfer buffer. 4 pieces of Whatman® paper were prepared and soaked in 
transfer buffer just prior to use. The blotting sandwich (2x paper – membrane – gel – 2x paper) was 
assembled and put into the blotting device (Bio-Rad Trans-Blot® Semi-Dry) according to the 
instructions. Proteins were transferred to the membrane by applying 22 V for 30 minutes. After 
transfer the membrane was rinsed with wash buffer PBS-T  and blocked with 5 % BSA in PBS-T for 1 
hour at 4°C under agitation. After incubation, the membrane was rinsed shortly with wash buffer and 
the primary antibody was added (anti-MKK7  1:1500, anti-β-actin  1:8000; both in 5 % BSA in PBS-T). 
The membrane was kept at 4°C on a shaker over night. The following day the membrane was washed 
extensively before the secondary antibody was added (anti rabbit-HRP to detect MKK7; anti mouse-
HRP to detect β-actin; both 1:10.000 in 5 % dry milk in PBS-T). Incubation was done at room 
temperature with agitation for 1 hour. The membrane was then washed extensively and protein 
expression detected using the Amersham ECL Plus Western Blotting Detection Reagents (GE 
Healthcare) according to the instructions. The resulting chemoluminescent signal was visualized on 
autoradiography films (Amersham Hyperfilm ECL , GE Healthcare). Detection of c-Jun protein was 
done in the same way with some minor modifications. Blocking was performed in 5 % milk in PBS-T for 
1 hour at room temperature under agitation. The c-Jun antibody (Cell Signaling) was diluted 1:500 in 5 
% BSA in PBS-T and incubated over night at 4°C. To detect the primary antibody, HRP-labeled anti-
rabbit antibody was used at a dilution of 1:5000 in 5 % milk in PBS-T for 1 hour at room temperature. 
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Transfer buffer Wash buffer PBS-T 
25 mM Tris Base PBS 
190 mM Glycine 0.1 % Tween20 
20 % Methanol  
 
3.2.10 ELISA 
 
All ELISAs were performed using kits from R&D Systems according to the manufacturer’s instructions. 
For determination of TNF-α or IL-6 levels liver lysates were diluted 1:30 with Reagent Diluent whereas 
spleen lysates were diluted 1:15. Sample preparation for detection of phospho-JNK was done as 
described in the manual. Measurement of the ODs at 450 and 560 nm wave length were performed on 
a microplater reader (Tecan). Cell death ELISAs (Cell Death Detection ELISA PLUS, Roche) were 
performed according to the instructions. 
 
3.2.11 RNA isolation 
 
Purification of total RNA from liver and spleen tissue was performed using the RNeasy Mini Kit 
(Qiagen) according to the protocol. Tissues were homogenized together with 350 µl Buffer RLT 
supplied with 3.5 µl β-mercaptoethanol using the Peqlab Precellys 24. After disruption of the tissue 
the manufacturer’s instructions were followed. RNA was eluted in 40 µl RNase-free water and 
concentrations were determined using the NanoDrop 1000 Spectrophotometer (Peqlab).  
 
3.2.12 cDNA synthesis and qPCR 
 
cDNA synthesis and qPCR were performed as described in section 3.1.2.4 and 3.1.2.5, respectively. A 
list of the used primers is shown below. 
 
Name Sequence 
MKK7-RTPCR_fwd TCCAGATCCCACCAAGCCTGACTATG 
MKK7-RTPCR_rev AATGACTGGAAGTCCCCTGAGAAGCC 
cJun-RTPCR_fwd GGGACACAGCTTTCACCCTA 
cJun-RTPCR_rev GAAAAGTAGCCCCCAACCTC 
JunB-RTPCR_fwd AGACACAGGCGCATCTCTGA 
JunB-RTPCR_rev CTGCTGAGGTTGGTGTAGAC 
JunD-RTPCR_fwd TTGAGGGTCTTGACTTTCTCCTCCA 
JunD-RTPCR_rev TTTCGCGGGTGGCGCCGGGCCCCCTGG 
iNOS-RTPCR_fwd GGCAGCCTGTGAGACCTTTG 
iNOS-RTPCR_rev CATTGGAAGTGAAGCGTTTCG 
Gadd45b-RTPCR_fwd CCAGTCGTTCTGCTGCGACAATGACAT 
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Gadd45b-RTPCR_rev CCTCCACCAAGCCTTGGCTTTTCCAGGAA 
TNFa-RTPCR_fwd AACTAGTGGTGCCAGCCGAT 
TNFa-RTPCR_rev CTTCACAGAGCAATGACTCC 
TGFb-RTPCR_fwd CACCGGAGAGCCCTGGATA 
TGFb-RTPCR_rev TGTACAGCTGCCGCACACA 
b-actin-RTPCR_fwd CCTGAACCCTAAGGCCAACCG 
b-actin-RTPCR_rev GCTCATAGCTCTTCTCCAGGG 
 
3.2.13 Embedding of fixed tissues 
 
After fixation overnight (Roti®-Histofix 4 %), tissues were first transferred to 70 % ethanol, then placed 
into tissue embedding cassettes and subjected to a series of different alcohol concentrations finally 
being infiltrated with paraffin. This process was done automatically by the Tissue-Tek® VIP® 5 Vacuum 
Infiltration Processor (Sakura). Tissues were then embedded into paraffin blocks and cooled for 
sectioning.  
 
3.2.14 H&E staining 
 
5 µm thick sections were layered on glass slides and dried overnight at 53°C. Sections were then 
dewaxed and stained (hematoxylin and eosin) automatically, mounted and sealed with a coverslip.  
 
3.2.15  TUNEL staining 
 
Paraffin sections were prepared as described above. After dewaxing they were stained with the In Situ 
Cell Death Detection Kit with Fluorescein (Roche) according to the protocol. For membrane 
permeabilisation a proteinase K solution (20 µg/ml in Tris-HCl, pH 7.5) was used. Sections were 
mounted in VECTASHIELD Mounting Medium with DAPI or VECTASHIELD HardSet Mounting Medium 
with DAPI (both Vector Laboratories) and protected with coverslips. Slides were scanned with the 
Mirax Scanner (Zeiss) and apoptotic areas were quantified by a computed algorithm developed by the 
BioOptics Facility of IMP-IMBA. 
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4 List of Abbrevations 
 
AA Acrylamide 
AB Antibody 
AFP α-fetoprotein 
AHF acute hepatic failure 
ALT  alanine aminotransferase 
AP alkaline phosphatase 
AP-1 activator protein 1 
APS ammonium persulfate 
ASK1 apoptosis signal-regulated kinase 1 
AST aspartate aminotransferase 
ATF2 activating transcription factor 2 
CCl4 carbon tetrachloride 
CMV cytomegalovirus 
ConA Concanavalin A 
DAPI 4′,6 -diamidin-2-phenylindol 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO dimethyl sulfoxide 
DV docking vector 
EB embryoid body 
EC embryonal carcinoma 
EDTA ethylenediaminetetraacetic acid 
EGC embryonic germ cell 
EGFP enhanced green fluorescent protein 
EGFR epidermal growth factor receptor 
ELISA enzyme-linked immunosorbent assay 
ERK1/2 extracellular signal-regulated kinase 1/2 
ESC embryonic stem cell 
EV exchange vector 
FADD Fas-associated death domain 
FCS fetal calf serum 
GalN  D-galactosamine 
GFP green fluorescent protein 
GOI gene of interest 
GPCR G protein-coupled receptor 
GTP  guanosine-5'-triphosphate 
HBV hepatitis B virus 
HCV hepatitis C virus 
HE hematoxylin and eosin 
HR homologous recombination 
ICM inner cell mass 
IL-1β interleukin-1β 
IL-6 interleukin-6 
INFγ interferon gamma 
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iPSC induced pluripotent stem cell 
IRES internal ribosome entry site 
JNK c-Jun NH2-terminal kinase 
LIF leukemia inhibitory factor 
LPS lipopolysaccharide 
MAF  musculoaponeurotic fibrosarcoma 
MAP2K mitogen-activated protein kinase kinase (= MAPKK, MKK) 
MAP3K  mitogen-activated protein kinase kinase kinase (= MAPKKK, MEKK) 
MAPK  mitogen-activated protein kinase 
MEF mouse embryonic fibroblast 
MHV-3 murine hepatitis virus strain 3 
MKK4  mitogen-activated protein kinase kinase 4 
MKK7 mitogen-activated protein kinase kinase 7 
MLK mixed lineage kinase 
MMTV mouse mammary tumor virus 
NF-κB nuclear factor-κB 
NO nitric oxide 
nos2 nitric oxide synthase 2 
OD optical density 
PBS  Phosphate buffered saline 
PGC primordial germ cell 
PGK phosphoglycerate kinase 
PH partial hepatectomy 
poly(I:C) polyinosinic-polycytidylic acid 
PyMT Polyoma Middle T 
RIP1 receptor interacting protein 1  
RNAi RNA interference 
ROS reactive oxygen species 
RTK receptor tyrosine kinase 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
shRNA short hairpin RNA 
siRNA small interfering RNA 
SSR site-specific recombinase 
TAK1 TGFβ-activated kinase 1  
TEMED Tetramethylethylenediamine 
TGFβ transforming growth factor β 
TNF-R1 tumor necrosis factor receptor 1 
TNF-R2 tumor necrosis factor receptor 2 
TNFα tumor necrosis factor α 
TRADD tumor necrosis factor receptor-associated death domain 
TRAF2 tumor necrosis factor receptor-associated factor 2 
TUNEL  Terminal deoxynucleotidyl transferase mediated dUTP Nick End Labeling assay 
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